1. TITLE PAGE
PROTOCOL  
A Phase 2 Angelman Syndrome Clinical Trial: A Randomized, Double -blind, Safety 
and Efficacy Study of Gaboxadol ( Short Name: STARS)  
Protocol No:  OV101 -15-001 
Investigational  Product:  Gaboxadol (OV101)  
Indication:  Angelman syndrome (AS)  
Sponsor:  Ovid Therapeutics  Inc. 
1460 Broadway  
New York, NY 10036  
USA  
Sponsor Signatory and Medical 
Lead:   
 
Ovid  Therapeutics  Inc. 
Steering Committee Meeting 
Chair:   
 
 
Development Phase:  Phase 2 
Date of the Protocol : 
Version of the Protocol : 4.0 (Amendment 3) 
The confidential information in this document is provided to you as an investigator, 
potential investigator or consultant for review by you, your staff and applicable 
Institutional Review Board (IRB). It is understood that the information will not be 
discl osed to others without written authori zation from Ovid Therapeutics Inc.  except to 
the extent necessary to obtain informed consent from those persons to who m the drug 
may be administered.  
Ovid Therapeutics  Inc. 
1460 Broadway  
New York, NY 10036  24 Oct 2017

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 2 of 83 2. TABLE  OF CONTENTS
1.TITLE PAGE  ................................ ................................ ................................ .............  1 
2.TABLE  OF CONTENTS  ................................ ................................ ..........................  2 
3.SPONSOR INFORMATION  ................................ ................................ ....................  8 
4.SIGNATURE PAGES  ................................ ................................ ...............................  9 
5.GENERAL INFORMATION  ................................ ................................ .................  10 
6.LIST OF ABBREVIATION S AND DEFINITION OF TERMS  ........................  12 
7.STUDY SYNOPSIS  ................................ ................................ ................................ . 14 
8.INTRODU CTION  ................................ ................................ ................................ ... 26 
8.1 Background and Overview of Angelman Syndrome  ................................ ...................... 26 
8.2 Study Rationale  ................................ ................................ ................................ .............. 28 
9.STUDY  OBJECTIVES AND ENDP OINTS  ................................ .........................  29 
9.1 Primary Objectives  ................................ ................................ ................................ ......... 29 
9.2 Secondary Objective  ................................ ................................ ................................ .......29 
9.3 Exploratory Objective  ................................ ................................ ................................ ....31 
10.STUDY DESIGN  ................................ ................................ ................................ .. 32 
10.1  Overall Study Design and Plan  ................................ ................................ ....................... 32 
10.1.1  Description  ................................ ................................ ................................ .. 32 
10.1.2  Schedule of Assessments  ................................ ................................ .............  32 
10.1.3  Study Assessments  ................................ ................................ .......................  35 
10.2  Discussion of Study Design  ................................ ................................ ............................ 40 
10.3  Risk/Benefit Assessment  ................................ ................................ ................................ 40 
11. SELECTION OF SUBJECT S ................................ ................................ ............  41 
11.1  Diagnosis and Main Criteria for Inclusion:  ................................ ................................ ....41 
11.2  Inclusion Criteria  ................................ ................................ ................................ ............ 41 
11.3  Exclusion Criteria  ................................ ................................ ................................ ........... 42 
11.4  Withdrawal of Subjects  ................................ ................................ ................................ ..43 
12. TREATMENT OF SUBJECT S ................................ ................................ ..........  44 
12.1  Identity of Study Treatment(s)  ................................ ................................ ....................... 44 
12.1.1  OV101  ................................ ................................ ................................ .........  44 
12.1.2  Placebo  ................................ ................................ ................................ ....... 44 
12.1.3  Administration of Study Treatments  ................................ ............................  44 
12.2  Study Treatment Packaging and Labeling  ................................ ................................ ......46 
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 3 of 83 12.2.1  Packaging  ................................ ................................ ................................ ... 46 
12.2.2  Labeling  ................................ ................................ ................................ ...... 47 
12.2.3  Storage  ................................ ................................ ................................ ........  47 
12.3  Blinding and Randomization to Study Treatments  ................................ ......................... 47 
12.4  Procedure for Breaking the Randomization Code  ................................ .......................... 47 
12.5  Subject Compliance  ................................ ................................ ................................ ........ 48 
12.6  Study Drug Accountability  ................................ ................................ ............................. 48 
12.7  Concomitant Therapy  ................................ ................................ ................................ .....49 
13. DISCONTINUATION OF S TUDY TREATMENT OR WI THDRAWAL OF
SUBJECTS FROM STUDY ................................ ................................ ...........................  50 
13.1  Withdrawal/Discontinuation of Individual Subjects  ................................ ...................... 50 
13.1.1  Withdrawal from the Study  ................................ ................................ .........  50 
13.1.2  Discontinuation of Study Drug  ................................ ................................ ... 50 
13.2  Study Termination  ................................ ................................ ................................ .......... 50 
14. EFFICACY ASSESSMENTS  ................................ ................................ .............  51 
14.1  Efficacy Assessments  ................................ ................................ ................................ .....51 
14.1.1 Gross Motor Ability/Function  ................................ ................................ ..... 51 
14.1.2  Fine Motor Ability/Function  ................................ ................................ ....... 52 
14.1.3  Sleep  ................................ ................................ ................................ ............  53 
14.1.4  (Mal)adaptive Behaviors:  ................................ ................................ ...........  54 
14.1.5  Clinical Change:  ................................ ................................ .........................  55 
14.1.6  Health -Related Quality of Life of the Ind ividual with AS  ...........................  55 
14.1.7  Health -Related Quality of Life – Impact on Caregiver:  .............................  55 
15. SAFETY ASSESSMENTS  ................................ ................................ ..................  56 
15.1  Suicidality  ................................ ................................ ................................ ....................... 56 
15.2  Physical Examination  ................................ ................................ ................................ .....56 
15.3  Vital Signs  ................................ ................................ ................................ ...................... 56 
15.4  Laboratory Assessments  ................................ ................................ ................................ .56 
15.5  Electroencephalogram Assessments  ................................ ................................ ............... 57 
15.6  Optional Biomarker Analysis  ................................ ................................ ......................... 57 
16. SAFETY DEFINITIONS, RECORDING, REPORTING , AND  
RESPONSIBILITIES  ................................ ................................ ................................ ..... 58 
16.1  Adverse Events  ................................ ................................ ................................ ............... 58 
16.1.1  Definitions  ................................ ................................ ................................ ... 58 
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 4 of 83 16.1.2  Overdose  ................................ ................................ ................................ ..... 63 
16.1.3  Pregn ancy  ................................ ................................ ................................ ... 63 
16.1.4  Medical Emergency  ................................ ................................ ....................  63 
16.1.5  Safety Responsibilities  ................................ ................................ ................  63 
17. STATISTICAL EVALUATI ON ................................ ................................ .........  65 
17.1  Sample Size and Power  ................................ ................................ ................................ ..65 
17.2 Statistical Methods  ................................ ................................ ................................ ......... 65 
17.2.1  General Considerations  ................................ ................................ ..............  65 
17.2.2  Statistical Analysis Sets  ................................ ................................ ...............  66 
17.2.3  Baseline, Efficacy, and Safety Variables  ................................ ....................  66 
17.2.4  Methods of Statistical Analyses  ................................ ................................ .. 68 
18. DIRECT ACCESS TO SOU RCE DATA/NOTES  ................................ ............  70 
19. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ . 71 
19.1  Conduct of the Study  ................................ ................................ ................................ ......71 
19.2  Study Monitoring ................................ ................................ ................................ ............ 71 
20. ETHICS  ................................ ................................ ................................ ................  72 
20.1  Institutional  Review Board  ................................ ................................ ............................. 72 
20.2  Written Informed Consent  ................................ ................................ .............................. 72 
21. DATA PROTECTION  ................................ ................................ ........................  74 
22. CONFLICT OF INTEREST  ................................ ................................ ...............  75 
23. CLINICAL TRIAL STEER ING COMMITTEE  ................................ .............  76 
24. CHANGES TO FINAL STU DY PROTOCOL  ................................ .................  77 
25. DATA HANDLING AND RE CORD KEEPING  ................................ ..............  78 
25.1  Electronic Case Report Forms/Source Data Handling  ................................ ................... 78 
25.2  Retention of Essential Documents  ................................ ................................ .................. 78 
26. FINANCING AND INSURA NCE  ................................ ................................ ...... 79 
27. REGISTRATION OF STUD Y AND DISCLOSURE OF RESULTS  .............  80 
28. SIGNATURE OF INVESTI GATOR  ................................ ................................ . 81 
REFERENCE LIST  ................................ ................................ ................................ ........  82 
Ovid Therapeutics Inc.  CONFIDENTIAL  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 5 of 83 List of Tables  
Table  1 Schedule of Assessments  ................................ ................................ ................  33 
Table  2 Study Titration Schedule  ................................ ................................ ................  45 
Table  3 Clinical Chemistry and Hematology Tests  ................................ .....................  57 
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 6 of 83 List of Figures  
Figure  1: Study Design  ................................ ................................ ...............................  32 
Ovid Therapeutics Inc.  CONFIDENTIAL  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 7 of 83 List of Appendices  
Not applicable  24 October 2017
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 8 of 83 3. SPONSOR INFORMATION
Ovid Therapeutics Inc. is the Sponsor of this study.  
Ovid Therapeutics  Inc. 
1460 Broadway  
New York,  NY 10036  
For urgent medical issue s that require the study’s Medical Director be contacted, please 
refer to the contact list for complete contact information.  
Ovid Therapeutics Inc.  may transfer any or all if its stu dy-related responsibilities to 
contract research organization and other third parties; however, Ovid retains overall 
accountability for these activities.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 9 of 83 4. SIGNATURE PAGES
SPONSOR SIGNATURE PAGE  
PROTOCOL  
A Phase 2 Angelman Syndrome Clinical Trial: A Randomized, Double -blind, Safety 
and Efficacy Study of Gaboxadol ( Short Name: STARS)  
Protocol No: OV101 -15-001 
Date (day/month/year)  
10/25/2017

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 10 of 83 5. GENERAL INFORMATION
PROTOCOL  
A Phase 2 Angelman Syndrome Clinical Trial: A Randomized, Double -blind, Safety 
and Efficacy Study of Gaboxadol ( Short Name: STARS)  
Protocol No: OV101 -15-001 
Sponsor:  Ovid Therapeutics  Inc. 
1460 Broadway  
New York, NY 10036  
USA  
Clinical Research Organization:   
 
 
 
 
Sponsor Medical Lead and 
Signatory   
 
 
 
 
 
Steering Committee Meeting 
Chair:   
 
 
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0  Page 11 of 83   
      
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
The Medical Monitor must be contacted in the event of any urgent safety issues. 
Ovid Therapeutics Inc.  is transferring responsibilities  as outlined  in the Transfer of 
Obligations document . 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 12 of 83  
6. LIST OF ABBREVIATION S AND DEFINITION OF TERMS  
ABC -C Aberrant Behavior Checklist – Community  
  
AE Adverse event  
AS Angelman syndrome  
  
ß-hCG  beta-Human chorionic gonadotrophin  
BID Twice daily  
  
  
CGI-I Clinical Global Impression – Improvement  
CGI-S Clinical Global Impression – Severity  
  
CI Confidence interval  
COA  Clinical outcomes assessment  
CTCAE  Common Terminology Criteria for Adverse Events  
D Day 
eCRF  Electronic case report form  
EEG  Electroencephalogram  
  
FAS Full analysis set  
FDA  Food and Drug Administration  
FXS Fragile X syndrome  
GABA  Gamma -aminobutyric acid  
GCP  Good clinical practice  
ICF Informed consent form  
ICH International Conference on Harmonization  
IRB Institutional review board  
IWRS  Interactive Web Response System  
MedDRA  Medical Dictionary of Regulatory Activities  
MM 
 Medical Monitor  
 
MMRM  Mixed model repeated measures  
  
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 13 of 83   
PT Preferred term  
QD Once daily  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Statistical Analysis Software  
  
  
SOC  System organ class  
SOL  Sleep onset latency  
SOP Standard operating procedure  
SS Safety analysis set  
TEAE  Treatment -emergent adverse event  
TST Total sleep time  
UBE3A/Ube3a  Ubiquitin protein ligase E3A  
ULN  Upper limit of normal  
USA  United States of America  
WASO  Wake after sleep onset  
  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 14 of 83 7. STUDY SYNOPSIS  
Name of Sponsor/Company:  
Ovid Therapeutics Inc.  
 
Name of Investigational Product:  
OV101  (gaboxadol)  
 
Name of Active Ingredient:  
OV101 ( gaboxadol)  
 
Protocol Number:  
OV101 -15-001 
 
Title of Study:  
A Phase 2 Angelman Syndrome Clinical Trial: A Randomized, Double -Blind, Safety and Efficacy Study 
of Gaboxadol ( Short Name: STARS)  
 
Version Number:  
Protocol  Version  4.0 
 
Study Indication:  
Angelman syndrome (AS)  
 
Study Rationale  
OV101 (gaboxadol) is being evaluated in Phase  2 studies of subjects with AS. This rare neuro -genetic 
disorder occurs in approximately 1 in every 15,000 live births and manifests as several distinct 
characteristics. Consistent clinical findings range in severity and include developme ntal delay, movement 
and/or balance disorder, and tremulous movement of limbs. Perhaps the most unique behavioral 
characteristic is the combination of a happy demeanor, smiling, and frequent bouts of laughter. Moreover, 
these individuals possess an easily excitable personality exhibited by hand -flapping or waving 
movements. Finally, these individuals suffer from motor dysfunction related to gait and balance, severe 
disruptions in sleep, impairments in speech, and frequent seizures with characteristic abnorm al 
electroencephalogram (EEG) patterns. Individuals with AS will require life -long care.  
OV101 is the first highly selective extrasynaptic gamma -aminobutyric acid (GABA) receptor agonist that 
binds to the α4 and δ -subunit  containing  extrasynaptic GABA receptors as an orthosteric agonist and may 
restore the deficit in tonic inhibition that has been associated with AS. This is unlike any other 
GABAergic agent, including benzodiazepines, zolpidem and other Z -drugs, neurosteroids and dru gs that 
act on GABA metabolism or uptake. Further, in a mouse model of AS, gaboxadol was shown to restore 
tonic inhibition in UBE3A -deficient cerebellar neurons and correct motor abnormalities in 
UBE3A -deficient mice.  
These results suggest that OV101 may a lleviate the motor dysfunction observed in individuals with AS. 
These potential effects on tonic inhibition may impact motor function in people with AS.  
Previous Phase 2 and 3 studies in subjects with primary insomnia suggest OV101 is effective in restorin g 
classical sleep parameters and slow -wave sleep, resulting in an improvement in the quality and restorative 
effects of sleep. One study using a transient insomnia model involving 100  subjects showed that 
administration of OV101 resulted in statistically s ignificant improvements on both sleep induction and 
sleep maintenance. More importantly, these effects were achieved without the risk of drug dependence.  
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 15 of 83  
 
Since the targeted study population may not be complian t with certain study assessm ents, the highest 
possible level of flexibility will be applied to the schedule of assessments at each study center visit, thus 
minimizing the risk of missing or confounded data, while data reliability is maintained.  
 
Phase of Development:  
Phase 2  
 
Study Design:  
Multicenter, randomized, parallel (3 -arm), double -blind, placebo -controlled  
 
Study Location:  
Approximately 15 specialized centers across the United States of America  and 1 specialized site in Israel  
 
Principal Investigator:  
 
 
Study Period (first subject first visit to database lock):  
1.5 year 
 
Estimated date of first subject first visit:  
1st Quarter 2017 
 
Estimated date last subject last visit:  
2nd Quarter 201 8 
 
Study Objectives and Endpoints:  
The primary objective  of the study is to evaluate the safety and tolerability of OV101 from Baseline to 
Week  6 and Week  12 in adolescent and adult  subjects with AS across different dose levels and in 2 dosing 
schedules.   
The following dosing schedules will be assessed  against placebo:  
• Once da ily (Q D): An evening dose titrated to the target dose of 15  mg unless not tolerated  
• Twice daily (BID): Evening and morning doses titrated to the target doses of 15  mg evening dose 
and 10  mg morning dose unless not tolerated  
The safety endpoints that relate to this objective are as follows:  
• Frequency and severity of adverse events (AEs) and serious adverse events  (SAEs)  
• Vital signs (weight, blood pressure, heart rate, and temperature)  
• Laboratory parameters (elect rolytes, lipids, glucose,  hepatic , renal and pancrea tic function tests, 
and hematology). It is in the discretion of the study center staff to apply local best practices to 
obtain a blood sample from the subject  
• Irritability will be assessed using the Aberrant Behavior Checklist – Community (ABC -C) in an 
attempt to assess suicidality  
• EEG  
• Caregivers will maintain an electronic seizure diary. Any clinically important changes, including 
changes in seizure medication, will be reported as a safety event  
• Physical Exam finding s 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 16 of 83  
 
 
 
 
 
 
 
  
   
   
    
 
   
   
 
 
  
    
  
  
 
 
   
  
 
 
    
  
  
  
  
  
  
  
  
  
 
 
 
  
  
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 17 of 83    
  
  
 
  
  
  
 
   
  
  
  
  
  
 
 
   
  
 
 
 
 
 
  
  
 
 
   
  
 
 
 
 
 
 
 
 
  
   
  
 
  
  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 18 of 83 ▪  
  
  
  
 
 
 
  
All safety and efficacy assessments will be performed as indicated in the schedule of assessments 
(Table  S2). Assessments such as laboratory sampling and EEG should be done towards the end of a visit 
to minimize any confounding impact on subject performance. Options to perform these safety assessments 
away from the study center prior to the study center visit will be assessed in collaboration with study 
center staff a nd approved by the Medical Monitor case by case, if required.  
Additional biomarker samples will be acquired from all subjects for whom the caregiver provides a 
separate informed consent for purification of DNA and plasma, to allow for identification of sec ondary 
pathogenic variants and metabolic profiles.  
 
Number of subjects (planned):  
Approximately 75  subjects will be enrolled. At the completion of the study, there will be approximately 
25 subjects in each of the 3 treatment groups: 1) single evening dose  2) morning and evening dose, and 
3) placebo.  
Sample size calculations for this study are based on the objective of estimating AE rates within each 
active treatment group. The sample size of 25  subjects per group provides sufficient precision for 
estimatio n of incidence of common AEs. For example, a 2 -sided 95% confidence interval (CI) for a true 
incidence of 25% will estimate that incidence with a 17% precision (half -width of the 95% CI).  
While the expected enrol lment is 25 subjects per treatment group, if  enrol lment expectations are not 
realized, the sample size may be as low as 20 subjects per group.  A sample size of 20 subjects per group 
provides sufficient precision for estimation of incidence of common AEs.  For example, a 2 -sided 95% CI 
for the true incidence of 25% will estimate that incidence with 19% precision.  
 
 
 
 
 
 
 
 
 
 
 
  
Methodology:  
All subjects will receive a morning dose (either OV101 or placebo) and an evening dose (either OV101 or 
place bo) during the entire duration of treatment. The 2 dosing schedules of OV101 will be assessed ; a 
single evening dose (Q D): based on what was previously clinically assessed in the treatment of sleep 
disorder; Schedule  A) and a morning plus evening dose (Sch edule  B: BID) designed to provide a more 
sustained exposure. Schedule  C is morning and evening placebo. All subjects will be up -titrated to the 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 20 of 83 • Day 1: Treatment can start on any day during the week. The  next up -titration will occur on 
Day 3. If the defined interval occurs during the weekend , a + 2 day window for next titration step 
is acceptable , but the investigator should consider scheduling the start of treatment appropriately 
to limit titration steps occurring during the weekend . All subjects wil l start with 1  capsule 
(OV101 or placebo) in the evening  
Given the potential effects with food:  
• For the morning dose, it is recommended that the study drug be given with or shortly after the 
morning meal  
• For the evening dose, it is recommended that study drug be given within 30  minutes of scheduled 
bedtime  
Target up -titration  
• Day 3 (window +  2 days) : If no AE related to the study drug is observed from the previous time 
point by caregiver and/or the investigator, another capsule (OV101 or placebo) is added in the 
evening  
• Day 7 (window +  2 days) : If no AE related to the study drug is observed from the previous time 
point by caregiver and/or the investigator, another capsule (OV101 or placebo) is added in the 
evening  
• Day 10 (window +  2 days) : If no AE related to the study drug is observed from the previous time 
point by caregiver and/or the investigator, another capsule ( OV101  or placebo) is added in the 
morning  
• Day 14 (window +  2 days):  If no AE related to the study drug is observed from the previous time 
point by caregiver and/or the investigator, another capsule (OV101 or placebo) is added in the 
morning  
Slowed up -titration  
If tolerability does NOT allow immediate further dose -escalation at any of the above detailed 
days (3, 7, 10, or 14), but if that is poss ible at subsequent visit (e.g. Day  10 instead of Day  7), 
also such delayed up -titration will be acceptable. In such a case, the investigator will record 
up-titration data during the additional phone titrations calls. Any intolerability will be 
documented a s an AE. 
Down -titration  
Modifications may be made per investigator judgment on urgent need or medical necessity. If 
tolerability is not acceptable (e.g. somnolence, dizziness, vomiting, or change in behavior) after a 
previous up -titration step or during th e 12 week s of treatment, the Investigator should discuss 
with the Sponsor MM  or his/her delegate  if necessary . Any such intolerability must  be 
documented as an AE. Once a tolerable dose has been reached, it shall remain constant for the 
duration of the tre atment period.  
Ongoing treatment  
• Day 14: Earliest day the target dose can be reached (10 mg [ 2 capsules ] in the morning and 
15 mg [3 capsules] in the evening) : if so, dosing should be kept stable until the End of T reatment 
visit (Week  12) unless intolerabi lity requires down -titration per the above described conventions  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 22 of 83 to attend scheduled study visits  to participate in all assessments described in the protocol  
5. Able to attend scheduled study visits and be willing to perform the required clinical evaluations  
6. Able to ingest  the study drug  
7. Caregivers must agree not to post any subject’s personal medical data related to the study or 
information related to the study on any website or social media site (e.g. Facebook, Twitter, etc.) 
until the study is completed  
Exclusion Criteria  
1. Non-ambulatory subjects (e.g. requiring a wheelchair) not able to perform the assessments of 
Motor Ability/Function  
2. Poorly controlled seizures defined as >  3 seizures lasting less than 3 minute s per week or 
> 1 seizure episode lasting more than 3 minute s per week  or as per medical monitor judgment  
3. Concomitant cardiovascular or respiratory diseases of a degree that would limit participation in 
the study  
4. Concomitant disease (e.g., gastrointestinal, renal, hepatic, endocrine or cardiovascular system 
disease) or condition or any clinically significant finding at screening that could interfere with 
the conduct of the study, or that would pose an unacceptable risk to the subject in this study.  
5. Any of the following laboratory abnormalities:  total bilirubi n >1.5 x upper limit of normal (ULN) 
(unless isolated Gilbert’s syndrome),  alanine aminotransferase or aspartate aminotransferase 
>2.5 x ULN; serum  creatinine >1.2 x  ULN ; absolute neutrophil count < 1.5 x 109/L, platelets 
< 80 x109/L, hemoglobin <80  g/L; TSH >1.25 x ULN or <0.8 x ULN.  
6. Pregnancy  
7. Women of child -bearing potential who are not using a double -barrier method of contraception 
(e.g. condoms plus oral contraceptives), with abstinence being an accepted method  
8. Concomitant use of minocycline, levodopa, z olpidem, zaleplon, eszopiclone, ramelteon  or 
benzodiazepines  for sleep , as well as,  cannabinoid derivatives , and any other use of any 
investigational agent, device, and/or investigational procedure 4  weeks prior to Baseline and 
during the study  
9. Allergy to OV101 or any excipients  
10. At increased risk of harming self and/or others based on investigator assessment  
11. Any condition or reason  that in the opinion of the investigator make s the subject unsuitable for 
enrollment  
12. Inability of subject or caregiver to comply  with study requirements  
 
Study periods, duration of treatment and follow -up:  
1. Screening ( up to 28 days ) if a subject needs a repeat lab or additional lab to confirm eligibility 
the screening period may be extended.  
2. Baseline visit (Day  1); full day visit  
3. Titration period (2  weeks); at least 4  titration  phone visits during that period  
4. Treatment until end of Week  12; at least 3 safety phone visits during that period  
5. Interim; full day visit at Week  6 
6. End of Treatment; full day visit at Week 12  
7. Follow -up perio d; the study center will have 1 phone visit ( 2 weeks after End of Treatment) to 
capture information on any AEs which occur after the End of Treatment visit  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4.0    Page 23 of 83 Statistical methods for analysis:  
Descriptive statistics will be used to summarize all primary and secondary endpoints as well as baseline 
variables, by treatment group. For continuous variables, n, number of missing values, mean, standard 
deviation, median, minimum, and maximum will be provided. For categorical variables, frequency and 
percentage will be presented for each category. The CIs will be provided where meaningful. All CIs will 
be 2-sided 95% CIs. All data collected during the study will be listed.  
The primary endpoint is the incidence of treatment  emergent adverse events (TEAE). The Safety An alysis 
Set (all subjects that received at least one dose of study drug) will be used for the analysis of the TEAEs. 
All AEs will be coded using the latest released version of Medical Dictionary of Regulatory Activities 
(MedDRA) and will be classified by Me dDRA system organ class (SOC), and preferred term (PT). The 
number and percentage of subjects who experience at least one TEAE as well as the number and 
percentage of subjects who experience at least one TEAE within each specific SOC and PT will be 
present ed by treatment group.  
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 26 of 83 8. INTRODUCTION
8.1 Background  and O verview of Angelman Syndrome  
Angelman syndrome (AS) is a rare neurogenetic disorder associated with  the deletion of 
or mutation in the Ubiquiti n Protein Ligase E3A gene ( UBE3A ). While expressed 
ubiquitously in the cells of  other tissues, in neurons the p aternal allele is preferentially 
silenced through the epigenetic process known as imprinting. Therefore, any alteration in 
the maternal copy of UBE3A  results in the expression of the AS phenotype.  The 
syndrome occurs in approximately 1 in every 15,000 live births and has several distinct 
characteristics . Clinical findings range in severity and may include developmental delay, 
movement and/or balance disorder, and tremulous movement of limbs . The most unique 
behavioral characteristic is the combination of a happy demeano r, smiling , and easily 
provoked . Moreover, these individuals possess a short attention span and an easily 
excitable personalit y exhibited by hand -flapping or waving movements . Finally, 
individuals with AS suffer from motor dysfunction related to gait and balance, severe 
disruptions in sleep, impairments in speech, anxiety, and frequent seizures with 
characteristic abnormal electr oencephalogram (EEG) patterns1.  
Current Therapies for Angelman Syndrome  
There are no current sp ecific treatments for AS . Clinical management includes 
management of symptoms including anti -epileptic medications for seizure control and 
oftentimes medication s for sleep or anxiety . Physical and occupational therapies, 
communication therapy, and behavioral therapies are important in allowing individuals 
with A S to reach their maximum developmental potential2. 
Pre-clinical  Experience  with OV101 
Research has shown that absence (or dysfunction) of UBE3A  results in an aberrant 
increase in the uptake of  gamma -aminobutyric acid (GABA), which the main inhibitory 
neurotransmitter in the brain. OV101 is the first highly selective GABA receptor agonist 
that binds to the α4 and δ -containing GABA A receptors. These receptors mediate tonic 
inhibition and contribute to sleep maintenance. Further, in a mouse model of AS, 
gaboxadol was shown to restore tonic inhibition in Ube3a-deficient cerebellar neurons 
and co rrect motor abnormalities in Ube3a-deficient mice3. 
These results suggest that OV101 may alleviate the motor dysfunction observed in 
individuals with AS. Importantly, OV101’s ability to potentiate tonic inhibition is unlike 
any other GABAergic agent, incl uding benzodiazepines, zolpidem, other Z -drugs, 
neurosteroids, and drugs that act on GABA metabolism or uptake.  
In addition to the data on presynaptic dysfunction leading to reduced tonic inhibition, 
there are additional studies which speak to the potential  of OV101 in AS, including 
modulation of sleep and cognition domains that are impaired in AS subject s4,5,6,7,8,9. 
 
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 27 of 83  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
Pharmacokinetics  
The pharmacokinetic profile of OV101  was similar whether administered in the morning 
or evening in the fasting state 11. There were also no differences between 
morning and evening pharmacokinetics when OV101  was given with food. A high -fat 
meal just prior to OV101  administration in the morning or evening delayed absorption by 
0.5 to 1  hours and decreased maximum concentration by approximately 30%, while 
exposure was practically unchanged compared with the fas ting state.  
Prior Clinical Experience  
OV101 was generally safe and well tolerated in all Phase  2 and 3 studies  in more than 
4300  subjects with insomnia, in non -elderl y adult subject s (aged 18 to 64  years) at doses 
up to 15  mg (in 1 early  Phase  2 study up t o 20  mg). In non -elderly adult subject s, the 
most common adverse events (AEs) occurring more frequently in OV101 -treated subject s 
than in subject s on placebo were dizziness, nausea, vomiting, somnolence, and headache. 
Most AEs were of mild to moderate inte nsity. Generally, tolerability was better in male 
than in female subject s. 
OV101  administration in the morning was safe at all doses 12. In healthy 
young men, doses up to 20  mg were well tolerated when given alone as single morning 
doses for 5  days. In young women, a 15  mg morning dose was not well tolerated or 
tolerated with considerable discomfort from Day  2 and onwards. An evening dose of 
15 mg was well tolerated in  young women and women above 55  years for 3 consecutive 
days. Therefore, a 10  mg morning dose was chosen for this study. The AEs with the 
highest incidences were dizziness, nausea, headache, and somnolence. The majority of 
AEs h ad a rapid onset (within 1 to 2  hours post -dose) and resolved after the drug was 
discontinued.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 28 of 83 Approximate ly 500  subjects were exposed to OV101 in c linical studies in 
non-insomnia -related development. The safety and tolerability profi le of OV101 in the 
non-insomnia -related studies was similar to that in sleep disorder studies. In general, the 
AEs seemed to be dose related, with no AEs reported for the 5  mg dose, and only mild 
AEs reported for the 10  mg dose of OV101.  
8.2 Study Rationale  
OV101  acts with high potency and efficacy at extrasynaptic α4  and δ -containing GABA A 
receptors which are not activated by benzodiazepines, or agents acting at the 
benzodiazepine binding site (such as zolpidem, zaleplon, indiplon, and zopiclone) . These 
extrasynaptic δ receptors are thought to be involved in mechanisms underlying tonic 
inhibition and sleep maintenance. In vivo  and in vitro  studies have shown that neither 
alcohol nor benzodiazepines potentiate the activity of OV101. In contrast to 
benzodiazepine receptor agonists, no withdrawal effects with OV101 are seen after 
chronic dosing . 
The possibility that OV101 may alleviate the motor dysfunction observed in individuals 
with AS and the ability of OV101 to potentiate tonic inhibition makes OV101 a candidate 
for potential tre atment of people with AS . 
Based on previous clinical experienc e, in  this study OV101 will be titrated  across 
different dose levels (15  mg evening dose and 10  mg morning dose) and in 3 dosing 
schedules for 12  weeks.  
The morning dose was selected based on a Phase  1 study in healthy volunteers which 
determined that a 10  mg morning dose had a comparable safety profile compared to 
placebo. The evening dose was selected based on the safety and efficacy data obtained 
from all studies conducted by H.  Lundbeck A/S and Merck in the indication of insomnia 
(reference to IND 64 ,567). 
This Phase  2 study will a ssess the safety and tolerability of oral OV101  in adolescent and 
adult  subjects with AS. In addition, multiple endpoints will be explored to identify the 
most appropriate efficacy outcome measures for future Phase  3 studies.  
This includes  all main AS symptom domains of gross and fine motor function, sleep, 
behavior, and health -related quality of life , with focus on motor ability and sleep.  The 
impact on caregivers will also be assessed . Questionnaires, diaries ,  will be 
used, complemented by more innovative outcome measures  (gait analysis ). 
Testing may be extensive for some of the study subjects, so the highest possible level of 
flexibility will be applied to the schedule of assessments at each study center  visit to 
minimize the risk of missing or confounded data, while maintaining data reliability . 
This study will be conducted in compliance with the protocol and with the International 
Conference on Harmoni zation (ICH) Good Clinical Practice (GCP).  More information 
can be found in the Investigator’s Brochure .10 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 29 of 83 9. STUDY OBJECTIVES  AND ENDPOINTS  
9.1 Primary O bjectives  
The primary objective of the study is to evaluate the safety and tolerability of OV101  
from Baseline to Week  6 and Week  12 in adolescent and adult subjects with AS across 
different dose levels and in 2 dosing schedules.  
The following dosing sc hedules will be assessed against placebo:  
• Once daily (Q D): An evening dose titrated to the target dose of 15  mg unless not 
tolerated  
• Twice daily (BID ): Evening and morning doses tit rated to the target doses of 
15 mg evening dose and 10  mg mo rning dose unless not tolerated  
The safety endpoints that relate to this objective are as follows:  
• Frequency and severity of AEs and serious adverse events ( SAEs)  
• Vital signs (weight, blood pressure, heart rate, and temperature)  
• Laboratory parameters (electrolytes, lipids, glucose, renal, hepatic  and pancrea tic 
function tests, and hematology ). It is in the discretion of the study center  staff to 
apply the best local  practices to obtain a blood sample  from the subject . 
Laboratory sampling should be done towards the end of a visit to minimize any 
confounding impact on subject performance  
• Irritability will be assessed using the Aberrant Behavior Checklist – Community 
(ABC-C), Irritability subscale as a surrogate measure for suicidality  
• EEG  
• Caregivers will maintain an electronic seizure diary. Any clinically important 
changes, including changes in seizure medication, will be reported as a safety 
event  
• Physical Exam findin gs 
9.2 Secondary Objective  
 
 
 
 
 
 
 
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 30 of 83   
  
  
   
  
  
   
  
 
 
  
  
 
 
  
  
  
  
  
  
  
  
   
  
 
 
 
 
  
 
 
  
  
  
 
 
  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 31 of 83   
 
   
  
  
  
  
  
 
  
  
9.3 Exploratory Obje ctive  
 
 
 
 
 
   
  
 
 
   
  
 
 
 
 
 
 
 
 
  
  
  
 
  
  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 35 of 83 10.1.3  Study Assessments  
Section  14 details the individual assessments . 
10.1.3.1  Screening Period  (Day -28 to Day  0) 
After obtaining a signed informed consent form (ICF) from the parent or legally 
authorized caregiver and assent as appropriate from the potential subject, individuals with 
AS will begin the study screening procedures for eligibility including clinical and 
laboratory evaluation and all measurements  used for efficacy assessment (sleep, motor 
function , and behavior) . Assent will be obtained if the investigator believes that the 
subject can provide  it depending on the subject’s intellectual ability, but ass ent may not 
be relevant for non -verbal subject s. 
Investigators will explain to caregivers the necessity to discontinue the intermittent use of 
sleep medication and not to introduce new medication during the study . 
 
 
 
 
Study centers will request a subject registration and treatment code centrally ge nerated by 
an Interactive Web Response System  (IWRS) (Section  12.3). No subject may begin 
treatment prio r to assignment of a unique identification number ( registration) and 
randomization. Any subject identification numbers that are assigned will not be reused, 
even if the sub ject does not receive treatment . 
Screening laboratory assessments will be performed.  
Caregivers will also be asked  to sign a separate ICF for the subject to provid e an 
additional blood sample (1  tube) at Baseline (and on Day  84 [Section  10.1.3.2 ]) to permit 
purification of DNA and plasma to enable identification of secondary pathogenic gene 
variants and allow for metabolic profiling. Those not consenting to this will still be 
eligibl e for the main study.  
All subjects will be screened for participation in the study up to 28  days prior to the first 
dose administration. Subjects who meet all criteria can be randomized at any time during 
the screening period. The screening assessments are  listed in Table  1. 
The caregiver will be provided with an e -Diary for documenting sleep and subject’s 
seizures  
 
 
 
. 
During the screening period, it will be determined by the Investigator whether or not the 
caregiver and subject are able to  comple te all questionnaires and assessments  that require 
their contribution to assess their ability to compl y with study procedures.   

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 36 of 83 For those without  documentation of a molecularly -confirmed  diagnosis, blood  samples 
will be obtained during the screening period and subjected to methylation sensitive 
polymerase chain reaction amplification of a portion of the small nuclear 
ribonucleoprotein polypeptide N  gene  and/or UBE3A  gene sequencing to confirm the 
diagnosi s of AS . 
 
 
 
 
  
Screening and Baseline assessments must be performed within the 28-day period. If the 
subject can perform the Screening and Baseline visit within 5 days, the following 
assessments do not need to be repeated at the Baseline visit (medical history, clinical 
assessment, physical examination, clinical laboratory tests, serum pregnancy test, and 
concomitan t medications ).  
Those not  meeting the inclusion criteria or meeting an exclusion criterion  will be 
considered a screen f ailure. It shall be discussed with Medical Monitor whether later 
rescreening is acceptable.  Rescreening may be allowed under circumstan ces where the 
subject passed the screening but could not be randomized within the 28 day  screening 
window due to logistical, personal or other unforeseeable reasons. Rescreening will only 
be allowed in cases where no safety risk is posed to the subject.   
If a screening test result (lab or any other tests) is considered uncertain  or abnormal , the 
test may be repeated to confirm the result after approval from the Medical Monitor. If a 
subject needs a repeat lab or additional lab to confirm eligibility the scr eening period may 
be extended.  
 
10.1.3.2  Treatment Period  (12 Weeks)  
Baseline Visit (Day  1; Full Day V isit) 
Eligible subjects will return to the study center  for the Baseline ( Day 1) visit . Caregivers 
will bring the e -Diary and wearables. Prior to randomization, study center  staff must  
confirm pr oper recording of the wearables, appropriate completion of the e -Diary, and 
fulfilment of all selection criteria.  
Subjects will be randomized on a 1:1:1  ratio according to the following dosing 
schedule:  
• Schedule A : a singl e evening dose of OV101 (Q D) plus morning placebo  
• Schedule B : a morning plus evening dose  of OV101  (BID ) 
• Schedule C : morning and evening placebo  
• Subjects will receive the assigned package of blinded study treatment as per 
treatment code for the titration period and until the next scheduled visit at Week  6 
• Baseline safety and efficacy assessments will be conducted  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 37 of 83 • Baseline laboratory assessments will be performed  
  
          
 
  
 
 
 
 
 
  
 
 
  
 
The e -Diary will be kept by the caregiver throughout the study. It must  be charged 
overnight each day by the caregiver. Study center  staff shall remotely check data 
completeness at least once a week and contact caregiver i f there is non -adherence , such as 
missing data.  
Titration (Day  1 to Day  14) 
Section 12.1.1  details the dosing schedule . 
During the titration period (Day  1 to Day  14), doses progressively increase in 5  mg 
increments according to the titration schedule, allowing slower up - or down -titration if 
the OV101  or placebo treatment is not tolerated ( Table  2) up to a target evening dose of 
15 mg ( 3 capsules ) in Schedules  A and B, and up to a target morning dose of 10  mg 
(2 capsules ) in Schedule  B. Multiple phone visits are scheduled to confirm tolerab ility of 
study treatment.  Each dose -escalation will be performed after adequate tolerability has 
been assessed by the caregiver and investigator during a phone visit. At any t ime, ad -hoc 
study center visits may occur  to further assess drug safety.  These should follow the script 
for phone visits.  
If the target dose is not achieved at Day  14 (due to slowed titration based on 
intolerability), the up -titration can continue until th e target dose or the maximum 
tolerated dose is reached. Additional phone visits to agree on next titration level will be 
performed.  As a general guidance for investigators, for subjects undergoing a slowed 
titration regimen, the maximal tolerated dose for the duration of the study should be 
reached by Day  21. 
Investigators will decide whether to up- or down -titrate  based on subject 
symptomatology , which should be  discussed with the Sponsor MM or his/her delegate as 
necessary . The study center  will d ocument each titration step in the  electronic case report 
form ( eCRF) and in source documents. The AEs triggering any slower - or down -titration 
will be recorded. Modifications may be made per investigator judgment based on urgent 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 38 of 83 need or medical necessity. If tole rability is not acceptable (e.g. somnolence, dizziness, 
vomiting, or change in behavior) after a previous up -titration step or during the course of 
the 12  weeks of treatment, the Investigator should discuss with the Sponsor MM or 
designee if necessary. Any  such intolerability must be documented as an AE. Once a 
tolerable dose has been reached, it shall remain constant for the duration of the treatment 
period.  The study  center will provide the caregiver with written dosing instructions  until 
the next titrati on step, by fax, e -mail, or during an unscheduled study center visit.  
Treat ment (Day  15 to Day  84); Until E nd of Week  12 
If the target d ose was not yet achieved at Day  14 (due to slowed titration based on 
intolera bility), up-titration can continue until the target dose or the maxi mum tolerated 
dose is reached. Additional phone visits to ag ree on next titration level will be performed.  
As a general guidance for investigators, for subjects undergoing a slowed titration 
regimen, the maximal tolerated dose fo r the duration of the study should be reached by 
Day 21. 
At D ays 30 and 6 0 (±2 days) the caregiver will courier the wearables back to the study 
center , because battery life will come to an end around that tim e. Study center staff will 
upload and check data  for any compliance or user errors. If errors are detected, the 
caregiver will be c ontacted to receive further instructions how to properly use the 
wearable. S tudy center  staff will courier a new set of wearables to the caregiver.  
Interim Visi t (Week  6; Fu ll Day V isit) 
During the Week  6 visit (Day  43, window ±3  days); subjects will make an interim full 
day study center visit to for the following procedures:   
• All scheduled safety and efficac y assessments will be conducted  
•  
          
 
  
 
 
 
 
  
 
 
  
 
 
• Additional phone visits are scheduled to confirm tolerability of study drug  
• If tolerability is  not acceptable (e.g. somnolence, dizziness, vomiting, or change in 
behavior) after a previous up -titration step or during the course of the 12  weeks of  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 39 of 83 treatment , the Investigator should discuss with the  Sponsor MM or de signee if 
necessary . Any such non -tolerabil ity must  be reported as an AE .  
End of Treatment ( Week  12; Full Day V isit) 
During the Week  12 visit (Day  84, window + 3 days); subjects will make a final full day 
study center visit for the following procedures:  
• Safety and efficacy assessments  
•  
          
 
  
  
 
 
 
• Caregivers will bring the e -Diary to the study center.  Any e-Diarie s no longer 
required will be returned  to the  at or before 
study center closure  
• Subjects will be asked to voluntee r an additional tube of blood to permit 
purification of DNA and plasma to enable identification of secondary pathogenic 
gene variants an d allow for metabolic profiling  
• The last dose of study drug should be taken the morning of the Day 84 visit if the 
subje ct is on the BID dosing regimen. After the last dose during the treatment 
period, d ownward titration of OV101 is not necessary given that in previous 
clinical studies with OV101, no withdrawal effects were observed after chronic 
dosing.  
10.1.3.3  Follow -Up Period (Day  85 to 98) 
During the follow -up period, the study center will have  1 phone visit ( 2 weeks after End 
of Treatment) to capture information on any AEs which occur  after the End of Treatment  
visit, using th e phone v isit script.  
10.1.3.4  Early Termination  
The study may be terminated at an individual study center if it becomes apparent that 
subject enrol lment is unsatisfactory with respect to quality and/or quantity. Study centers 
may also be closed if they prove to be unable to comply with the requirements of the 
protocol or GCP, or data recording is inaccurate and/or incomplete. If the study is 
terminated in an individual study center  for any reason, the investigator must make every 
effort to follow -up all subjects as planned according to the protocol. Replacement of  
study center s is allowed and new study center s may be initiated. An initiative for study 
center closure or study termination can be taken at any time either by Ovid Therapeutics 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 40 of 83 Inc. or by the investigator, provided there is reasonable cause and sufficient notice is 
given in advance of the intended termination.   
See Section 13 for early withdra wal from study.  For early withdrawal, subject should 
follow  Week 12 study visit schedule of assessment for safety measure which include 
medical history, clinical assessment, ABC -C irritability subscale, physical examination, 
clinical lab test, serum pregna ncy test, concomitant medications. Efficacy assessments do 
not need to be completed . 
10.2 Discussion of Study Design  
Neither  the investigators nor the subjects will be aware of the treatment assignments, to 
minimi ze any subjective or unrecognized  bias in reporting . Placebo  will be used as the 
comparator.  
Based on the potential reproductive effects observed in pre -clinical studies, 
pre-menopausal females  who have a positive  pregnancy test at the screening or b aseline 
visits, or those who are not able to use  an effective method of contraception (with 
abstinence being an accepted method), will be excluded from the study.  
Pre-clinical and clinical data suggest that the doses prescribed in this study will likely be 
therapeutically relevant and well -tolerated.  
A variety of scales will be employed for the exploratory assessment of safety and 
exploratory efficacy endpoints (Section  13).  
10.3 Risk/Benefit Assessment  
In adult subject s, the most common AEs occurring more frequently in OV101 -treated 
subject s than in subject s on placebo have been dizziness, nausea, vomiting, somnolence , 
and headache . Most AEs have been mild to moderate severity . OV101  is genera lly 
tolerated better by male s than female s and has been generally safe and well tolerated in 
Phase 2 and 3 insomnia studies in adult subject s at doses up to 15  mg and in the elderly at 
doses up to 10  mg. 
OV101  is rapidly absorbed and eliminated when given orally at doses of 10 to 40 mg . 
The m aximum plasma concentration is reached after half  to 1 hour, the elimination 
half-life is approximately 1.5 hours  and there is n o evidence of accumulation after 5 days 
of m ultiple dosing.  Pharmacokinetic data from the adolescent PK study OV101 -16-001 
with a single 5 mg oral administration to adolescent male and female subjects with FXS 
or AS suggest the exposure of OV101 is comparable to young adult subjects  given the 
same d ose. The dosing recommendation for adolescents in this study is therefore the 
same as for adults.  
Close monitoring of safety  will be conducted throughout this study.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 41 of 83 11. SELECTION OF S UBJECTS  
11.1 Diagnosis and Main Criteria for I nclusion:  
Adolescents and adults  with a molecular ly-confirmed  diagnosis of AS will be eligible for 
inclusion in the study. See Section 10.1.3.1  for testing of individuals who do not  have 
documentation of diagnosis.  
After obtaining signed informed consent from the  legally authorized representative (e.g. 
parent or caregiver)  and assent as appropriate from the potential subject, an individual 
with AS will begin the study screening proce dures to confirm  eligibility . The screening 
procedures to confirm eligibility will include  clinical and laboratory evaluation as well as  
all measurements  to assess exploratory efficacy  (sleep, motor function, and behavior ).  
Those  who do  not consent to the gene biomarker sampling will still be eligible to 
participate  in the STARS study .  
 
 
 
 
 
 
For those individuals not possessing documentation of a molecularly confirmed AS 
diagnosis, DNA samples will be obtained during the screening period to confirm the 
diagnosis of AS.  
If a subject needs a repeat lab or additional lab to confirm eligibility the screening period 
may be extended.  
11.2 Inclusion Criteria  
A subject will be eligible for enrol lment in the study if ALL of the following criteria 
apply:  
1. Age ≥ 1 3 years, ≤ 49 years at the time of informed consent  
2. Mole cular confirmation of AS  
3. Receiving a stable dose of concomitant medications  such as  anti-epileptic 
medication, gabapentin, clonidine, melatonin, trazadone, supplements, special 
diets for at least 4  weeks pri or to Baseline; and able to maintain these throu ghout 
the duration of the study  
4. Has a parent or caregiver capable of providing informed consent on behalf of the 
subject and able to attend scheduled study visits to participate in all assess ments 
described in the protocol  
5. Able to attend scheduled study visits and be willing to perform the required 
clinical evaluations  
6. Able to ingest the study drug  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 42 of 83 7. Caregivers must agree not to post any subject’s personal medical data related to 
the study or information related to the study o n any web site or social media site 
(e.g. Facebook, Twitter, etc.) until the study is completed  
11.3 Exclusion Criteria  
A subject will NOT  be eligible for this study if any  of the following criteria apply:  
1. Non-ambulatory subjects (e.g. requiring a wheelchair) not able to perform the 
assessments of Motor Ability/Function  
2. Poorly cont rolled seizures defined as >  3 seizures lasting less than 3 minute s per 
week or >  1 seizure episode lasting more than 3 minute s per week  or as per 
medical monitor  judgment  
3. Concomitant  cardiovascular or respiratory diseases of a degree that would l imit 
participation in the study  
4. Concomitant disease (e.g., gastrointestinal, renal , hepatic, endocrine or 
cardiovascular system disease) or condition or any clinically significant finding at 
screening that could interfere with the conduct of the study, or that would pose an 
unacceptable risk to the subject in this study  
5. Any of the following laboratory abnormalities:  total bilirubin >1.5 x upper limit 
of normal (ULN) (unless isolated Gilbert’s syndrome),  alanine aminotransferase 
or aspartate aminotransferase > 2.5 x ULN; serum  creatinine  >1.2 x  ULN ; absolute 
neutrophil  count < 1.5 x 109/L, platelets <  80 x109/L, hemoglobin <80  g/L; 
TSH  >1.25 x ULN or <0.8 x ULN  
6. Pregnancy  
7. Women of child -bearing pot ential who are not using a double -barrier method of 
contraception (e.g. condoms plus oral contraceptives), with abstinence being an 
accepted method  
8. Concomitant use of minocycline, levodopa, zolpidem, zaleplon, eszopiclone, 
ramelteon or benzodiazepines for sleep,  as well as, cannabinoid derivatives, and 
any other use of any investigational agent, device, and/or investigational 
procedure 4 weeks prior to Baseline and during the study  
9. Allergy to OV101 or any exci pients  
10. At increased risk of harming self and/or others b ased on investigator assessment  
11. Any condition or reason that in the opinion of the investigator , make s the su bject 
unsuitable for enrol lment  
12. Inability of subject or caregiver to comply with study requirements  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 43 of 83 11.4 Withdrawal of Subjects  
A subject may voluntarily withdraw at any time and for any reason. If a subject 
withdraw s, at his or her request  or at the  request of his or her caregiver or legal 
representative, the reason(s) must be recorded on the relevant page of the subject’s eCRF. 
Subjects who withdraw from the study prematurely should undergo all end -of-study 
assessments where possible. It is vital to obtain follow -up data on any subject withdrawn 
because of an AE. In any case, every effort must be made to undertake protocol -specified 
safety follow -up procedures. If a subject refuse s to continue with study procedures, the 
reason for refusal should be fully documented in the subject’s source document and 
recorded in the study specific eCRF.  Subjects who withdraw from the study prior to  
completing the final follow -up visit may be replaced at the discretion of Ovid 
Therapeutics Inc .  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 44 of 83 12. TREATMENT  OF SUBJECTS  
12.1 Identity of Study Treatment (s) 
12.1.1  OV101  
      
 
 
 
 
   
   
   
   
   
 
 
12.1.2  Placebo  
Placebo will be provided as a visually matching capsule, without active ingredient.  
12.1.3  Administration  of Study Treatment s 
OV101 will be supplied as a 5  mg capsule, and matching placebo, in bottles.  The 
caregiver will receive a sufficient number of capsules in 1  bottle “M orning” and 1  bottle 
“Evening”  at the b aseline visit and at the Week  6 interim visit . 
All subjects will receiv e a morning dose of OV101  or placebo a nd an evening dose of 
OV101 or placebo  during the entire duration of treatment . Two dosing schedules of 
OV101  will be assessed ; a single evening do se (Schedule A : QD) based on what was 
previously cl inically assessed in the treatment of sleep disorder, and a morning plus 
evening dose ( Schedule B : BID ) designed to provide a more sustained exposure.  
Schedule C is morning and evening placebo  (BID). All subjects will be up -titrated to the 
target dose unle ss this target dose is not tolerated (for titration conventions see below) . 
All subjects will receive treatment for a maximum of 12 weeks at their highest  tolerated 
dose.  The last dose of study drug should be taken the morning of the Day 84 visit if the 
subject is on the BID dosing regimen . 
Given the potential effects with food previously described:  
• For the morning dose, it is recommended that the study drug be given with or 
shortly after the morning meal  
• For the evening dose, it is recommended that study drug be given within 
30 minutes of scheduled bedtime  
The capsules can be opened and content added to one spoon of semi -liquid food 
(applesauce, pudding etc.).  CAPSULE CONTENT  CANNOT BE PLACED IN LIQUID. 
It must be documented specifically how the capsules were taken e.g. swallowed whole or 
taken in one spoon of applesauce or other food.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 46 of 83 12.1.3.4  Target Up -Titration  
Day 3 (window +  2 days): If no AE related to study treatment is observed from the 
previous time  point by caregiver and/or the investigator, another OV101  or placebo 
capsule is added in the evening.  
Day 7 (window +  2 days): If no AE related to the study treatment is observed from the 
previous time  point by caregiver and/or the investigator, another OV101  or placebo 
capsule is added in the evening.  
Day 10 (window +  2 days): If no AE related to the study treatment is observed from the 
previous time  point by caregiver and/or the investigator , another OV101  or placebo 
capsule is added in the morning.  
Day 14 (window +  2 days): If no AE related to the study treatment is observed from the 
previous time  point by caregiver and/or the investigator, another OV101  or placebo 
capsule is added in the mo rning.  
12.1.3.5  Slowed Up -Titration  
If tolerability does NOT allow immediate further dose -escalation at any of the above 
detailed days  (3, 7, 10, or 14), but does at subsequent visit (e.g. Day  10 instead of Day  7), 
delayed up -titrat ion will also be acceptable. In this case, the investigator will record 
up-titration data during the additional phone titrations calls. Any such intolerability must 
be documented as an AE. 
12.1.3.6  Down -Titration  
Modifications may be made per investigator judgment on urgent need  or medical 
necessity. If tolerability is not acceptable (e.g. somnolence, dizziness, vomiting, or 
change in behavior) after a previous up -titration step  or during the course of the 12  weeks 
of treatment,  the Investigator should discuss with the Sponsor MM  or his/her delegate if 
necessary.  Any such intolerability must be documented as an AE. Once a tolerable dose 
has been reached, it shall remain constant for the duration of the treatment period.  
12.1.3.7  Ongoing Treatment  
Day 14: Earliest day the target dose can be  reached (10 mg [2 capsules ] in the morning 
and 15 mg [ 3 capsules] in the evening) : if so, dosing should be kept stable  until End of 
Treatment visit (Week  12) unle ss intolerability requires down -titration according to the 
above described conventions . 
12.2 Study Treatment Packaging and Label ing  
12.2.1  Packaging  
OV101  will be supplied as a 5  mg capsule, and matching placebo, in 75 mL bottles  
containing 90  capsules for morning and 1 20 mL bottles containing 140  capsules for 
evening . The caregiver will receive a “Morn ing” bottle and an “E vening” bottle at 
Baseline and Week  6, respectively. Depending on the a llocated treatment group, the 
“Morning” or “E vening” bottles will contain the following:  
• Group A (Q D): Morning – Placebo/ Evening – OV101  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 47 of 83 • Group B ( BID): Morning – OV101 /Evening – OV101  
• Group  C (Placebo): Morning – Placebo/ Evening – Placebo  
12.2.2  Labeling  
Bottles containing OV101  or matching placebo, will have color tinted labels marked 
“Morning”  (yellow label)  or “E vening” (blue label) . Labels  will include the Sponsor 
Nam e (Ovid Therapeutics Inc. ), protocol number, bottle number (based on 
randomization), expiration date, n umber of c apsules (each bottle), “Morning” or 
“Evening” and “Take as directed”, as well as storage  specifications.  Each bottle will be 
labeled with an En glish and Spanish label.  Bottles and study treatment will be distributed 
by unique bottle number as designated by the IWRS and bottle quantities will be supplied 
to each study center in accordance with IWRS.  
12.2.3  Storage  
Study treatment must be received by a designated person at the study center , handled and 
stored safely and properly, and kept in a secured location to which only the investigator 
and designated staff have access. Study treatments are to be dispensed only in accordance 
with the protocol. The in vestigator is responsible for keeping accurate records of study 
treatment supplies received from Ovid Therapeutics Inc. , the amount dispensed to and 
returned by the subject s, and the amount remaining at the conclusion of the study.  Study 
treatment should b e stored at ≤  86°F.  
12.3 Blinding and Randomi zation to Study Treatment s 
This is a double -blind, placebo -controlled study . Investigators, study staff, and study 
subjects will be blinded to the randomized study treatment assignments . Both 
randomization and blindi ng techniques will be used in this study to minimize bias. A 
computer -generated randomization schema will be centrally available via IWRS  to all 
clinical centers that meet the requirements for participation in the study. The IWRS 
system can be accessed by individuals who have been issued a user ID and password , 
such as individuals at the study center or individuals from  
 
 
 Caregivers and investigators will also be asked at the 
End of Treatment visit whether they believe the subject was in an OV101 or placebo 
treatment arm.  
12.4 Procedure for Breaking the Randomiz ation Code  
In most cases, study drug unblinding will not be necessary . In a medical emergency 
where knowledge of the subject’s treatment assignment may influence th e subject’s 
clinical care, the i nvestigator, and if applicable, designated perso nnel at  may 
access the subject’s treatment assignment . The study center  investigator and appropriate 
 project team members will be authori zed to access the emergency unblinding 
functionality within the IWRS . The system will require the user to enter an authori zation 
key number to complete the emergency unblinding transaction . The exact description of 
the treatment assigned to the individual subject then will be accessible . Emergency 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 48 of 83 unblinding can thus be made for any subject without affecting t he double -blind nature of 
the study . Subject treatment  information may only be accessed in the event of an 
emergency and out of necessity to know the identity of the allocated study drug to 
institute appropriate therapeutic management . The investigator sho uld make every effort 
to discuss the rationale for emergency unblinding with the  Medical Monitor prior 
to unblinding the individual subject . Emergency unblinding should only be considered in 
situations where the knowledge of the treatment code has an impact on the plan ned 
treatment of the emergency . Once the randomi zation code is broken for a subject, he/she 
must be withdrawn from the study.  
Should a situation arise where unblinding is urgently required  (i.e. knowledge of 
treatment code is required to adequately manage a life -threatening situation) , the 
investigator at that study center  may perform immediate unblinding through IWRS 
without the need for communication with the  Medical Monitor.  
In the event that emergency unblinding is performed, the investigator can view and must 
print the blinded confirmation document from IWRS . The investigator must record on the 
confirmation document printout the reason for the emergency unblinding, and sign the 
document . The confirmation document must then to be kept in a safe place until the end 
of the study . Once a randomi zation code has been broken, the investigator must inform 
the  Medical Monitor in writing within 24  hours . The i nvestigator is strongly 
advised not to divulge the subject’s treatment assignment to any individual not directly 
involved in managing the medical emergency, nor to personnel involved with the analysis 
and conduct of the study . The i nvestigator can contact Ovid Therapeutics Inc.  or their 
designee to discuss such situations  without divulging subject’s treatment assignment . 
12.5 Subject Compliance  
Study drug compliance will be assessed by the investigator and/or study center staff by 
recording capsule counts of study treatments from the previously dispensed capsules, 
separately for “Morning” and “Evening” bottles. The investigator and/or study center 
staff will also assess whether the subject has been given the capsules in the prescribed 
order. The total number of doses administered to each subject will be derived from dosing 
information recorded in the eCRF.  
Caregivers must bring the bottles back at  each study center visit. Any remaining capsules 
will be counted and recorded to assess  compliance . Caregivers shall be questioned as to 
the reason why remaining capsules have not been administered (e.g. forgot because not 
part of routine, subject refused,  subject had side effects so parent decided to give a drug 
holiday, couldn’t open the bottle, down -titration recommended by doctor, etc .) and the 
approximate time of any missed doses.  
12.6 Study Drug Accountability  
Records shall be maintained of the delivery of  study drugs  to the study cent ers, the 
inventory at the study cent ers, the use by each subject  and the return to Ovid Therapeutics 
Inc. 
These records shall include dates, quantities, batch numbers, expiry dates and the unique 
code numbers assigned to the study drug  and to the study subjects.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 49 of 83 The investigator shall be responsible for ensuring that the records adequately document 
that the subjects were provided the doses specified in the protocol and that all study drug  
received from Ovid Therapeutics Inc.  is reconciled. All randomi zation codes must be 
returned to Ovid Therapeutics Inc.  at the end of the study.  
After completion of the study , all unused study drug will be inventoried and returned to 
Ovid Therapeutics Inc.  or as directed by the m. 
12.7 Concomitant Therapy  
Medication other than those listed in the Exclusion Criteria (Section 11.3) that are  given 
at stable dose for at least 4  weeks prior to Base line (e.g. constant use of sleep or 
anti-epileptic  medication) are acceptable, and must  be documented in the eCRF.  
Any changes in dose should be avoided during the study  and, if felt necessary, be 
previously discussed with the Medical Monitor.  
Medication s that are  not prohibited and considered necessary for the subject’s safety and 
well-being may be given during the study  at the discretion of the investigator and must be 
recorded in the appropriate sections of the eCRF.  
All prior medications taken within 3 0 days and ongoing concomitant medication must be 
documented in the eCRF.  
Subjects must be receiving a stable dose of concomit ant medications, including 
anti-epileptic medication, gabapentin, clonidine, melatonin, trazadone, supplements, an d 
special diets,  for at least 4  weeks prior to Baseline, and be able to maintain these 
through out the study. Modifications may be made per investigator judgment  based on 
urgent need or medical necessity . Subjects with questions about allowed concomitant 
therapy should seek medical guidance from the i nvestigator.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 50 of 83 13. DISCONTINUATION OF S TUDY TREATMENT OR WI THDRAWAL OF 
 SUBJECTS FROM STUDY  
13.1 Withdrawal/Discontinuation of Individual Subjects  
The reasons for study drug discontinuation and/or subject withdrawal from the study 
must be  recorded in the subject ’s eCRF . The investigator must notify Ovid Therapeutics 
Inc. and/or the Medical Monitor immediately when a subject has been 
discontinued/withdrawn  due to an AE.  
13.1.1  Withdrawal from the Study  
Subjects or their caregiver may withdraw subj ects from the study at any time for any 
reason without  compromising the subject’s medical care. The investigator may also 
withdraw subjects from  the study.  
Subjects who withdraw from the study prior to the End of Treatment  visit should 
complete the procedures  scheduled for that visit. T he reason for subject  withdrawal will 
be recorded in the eCRF.   
Withdrawal of subjects for any reason should be discussed with the Medical Monitor.  
13.1.2  Discontinuation of Study Drug  
If it is necessary to discontinue the study drug earlier than planned, subjects should 
continue to be  followed per protocol to capture safety and efficacy assessments for the 
duration of the study period  if feasible . 
The investigator may withdraw the subject from the study drug for the followi ng reasons:  
• Upon subject’s or caregiver’s request  
• The subject or caregiver is unwilling or unable to adhere to the protocol -specified 
visits  
• The subject experiences an intolerable AE  
• During the study , the subject develops symptoms or conditions listed in t he 
exclu sion criteria  
• Other medical reason, at the discretion of the investigator and/or the Medical 
Monitor  
Subjects who discontinue the study due to an AE considered related to study drug should 
be followed until the event is resolved, considered stable,  or the investigator determines 
the event is  no longer clinically significant. Study drug discontinuation due to AEs 
considered not related to  study drug will be followed until resolution . 
13.2 Study Termination  
The study, or any portion of it, may be terminated at any time for safety reasons  including 
the occurrence of AEs or other findings suggesting unacceptable risk to subjects,  
administrative, or operational reasons.  Study centers  must promptly notify their IRB  and 
initiate withdrawal pr ocedures for participating subjects.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 51 of 83 14.  
 
  
 
 
 
 
 
 
 
 
 
 
14.1 Efficacy Assessments  
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 52 of 83   
 
 
 
 
  
  
         
 
 
 
 
 
 
         
 
 
  
          
         
        
 
 
 
 
 
  
    
 
 
 
  
 
 
 
 
 
 
 
 
  
 
  
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 53 of 83  
 
 
 
 
  
        
 
 
 
 
 
 
 
 
  
 
 
  
  
  
  
  
  
  
  
   
 
 
 
 
 
    
 
 
 
 
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 54 of 83  
 
 
 
 
 
 
  
  
  
 
  
  
  
  
14.1.4  (Mal)adaptive Behaviors:  
• The Aberrant Behavior Checklist - Community ( ABC -C) is a rating scale that 
measures the severity of a range of problem behav iors commonly observed in 
individuals with intellectual and developmental disabilities17. It is completed by  
the caregiver. It is an empirically developed scale designed to measure psychiatric 
symptoms and behavioral disturbance exhibited by individuals acr oss 5  domains  
with 58  items: irritability, agitation, and crying  (15 items), lethargy, social 
withdrawal  (16 items), stereotypy (7  items), hyperactivity/noncompliance 
(16 items), and inappropriate speech (4  items) . Most individuals with AS are not 
able to communicate thoughts of suicidality, so subject irritability reported by the 
caregiver is being used as a surrogate measure of suicidality.  
• The ABC –C Irritability subscale will be used as an indicator for 
suicida lity. The investigator will review the scale items with the caregiver 
at each scheduled time point. If grading worsens, the investigator must 
decide whether that indicates a suicidal ideation of the subject, and if so, 
must document it as an AE and closely  monitor it until resolution. The 
ABC -C Irritability subscale will be used to assess risks of suicidality 
(safety variable).  The Aberrant Behavior Checklist  was developed for use 
with individuals living in institutions and residential settings. Revisions t o 
the measure have made it more applicable for home and school settings; 
the commonly used measure is now the ABC -C version.  
•  
 
        
          
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 55 of 83 14.1.5  Clinical Change:  
Clinical Global Impressions (Severity [CGI -S] and Improvement [CGI -I] scales). 
Both  scale s will assess all sub -domains of AS (gross and fine motor ability, sleep, 
and adaptive behavior) and will be filled out  by the caregiver and investigator. For 
the CGI -S, the rating should be relative to al l people, including typically 
developing individuals in the community. This rating is based upon observed and 
reported symptoms, behavior, and function. The CGI -I rates total improvement 
compared to the subject’s condition at baseline.  
 
        
      
 
         
        
 
            
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 56 of 83 15. SAFETY ASSESSMENTS  
Details for safety assessments are provided below. Details regarding the management of 
AEs are provided in Section 16. 
15.1 Suicidality  
Most individuals with AS are not able to communicate thoughts of suicidality, so subject 
irritability reported by the caregiver is being used as a surro gate measure of suicidality . 
The ABC –C Irritability  subscale  will be used as an indicator for suicidality. The 
investigator will review the scale items with the caregiver at each scheduled time point. If 
grading worsen s, the investigator must decide whether that indicates a suicidal ideation of 
the subject , and if so, must document it as an AE and closely monitor it until resolution.  
15.2 Physical Examination  
A physical examination should be performed at each visit to evaluate the medical 
condition of the subject and detect any sign/symptom of AEs, and to perform all the 
procedures required per protocol.  
A full physical examination will include a relevant  general assessment of: head, eyes, 
ears, nose and throat; neck; heart; chest (including lungs); abdomen ; extremities; skin; 
lymph nodes; as well as neurological and cardio vascular  system s. 
15.3 Vital Signs  
The following vital signs will be recorded during this study (this must include but not be 
limited to the measurement of changes in heart rate and blood press ure):  
• Heart rate  
• Blood pressure  
• Body temperature  
• Weight  
15.4 Laboratory Assessments  
Blood samples will be collected for routine clinical laboratory safety evaluations. Study 
center staff can apply the best local practices to obtain a blood sample in this population.  
Additional laboratory safety evaluations will be performed at other times, if judged to be 
clinically appropriate, or if the ongoing review of the data suggests a more detailed 
assessment of laboratory safety evaluations is required. Any change s to the scheduled 
times of laboratory safety tests will be agreed with  and Ovid Therapeutics Inc.  and 
documented. The investigator will perform a clinical assessment of all laboratory safety 
data.  
Laboratory parameters include electrolytes, lipids, g lucose, renal, hepatic  and pancrea tic 
function tests, and hematology. A serum pregnancy test will be done for female  subjects 
at the times noted in Table  1. 
Table  3 lists the clinical chemistry and hematology tests planned for this study.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 57 of 83 Table  3 Clinical Chemistry and Hematology Tests  
Clinical Chem istry  Hematology  
Albumin  Basophils (absolute)  
Alkaline phosphatase  Eosinophils (absolute)  
Alanine aminotransferase  Lymphocytes (absolute)  
Aspartate aminotransferase  Monocytes (absolute)  
Bicarbonate  Neutrophils (absolute)  
Calcium  Basophils  
Chloride  Eosinophils  
Cholestero l Hematocrit  
Creatine kinase  Hematology slide  
Creatine, enzymatic  Hemoglobin  
Direct bilirubin  Lymphocytes  
Glucose, random, serum  Monocytes  
High density lipoprotein cholesterol  Neutrophils  
Indirect bilirubin  Platelets  
Lactate dehydrogenase  Red blood cells  
Low density lipoprotein cholesterol, calculated  White blood cells  
Phosphorous  - 
Potassium  - 
Sodium  - 
Total bilirubin  - 
Total protein  - 
Triglyceride  - 
Urea (blood urea nitrogen)  - 
Uric acid  - 
Total cholesterol  - 
Magnesium  - 
Thyroid stimulating hormone  - 
15.5 Electroencephalogram Assessments  
EEG will be assessed as change s in background rhythms and the frequency of 
epileptiform discharges. Study centers will perform a routine EEG with local equipment.  
EEG should be done towards the end of a visit to minimize any confounding impact on 
subject performance. Standard protocol and montage will be followed as outlined in the 
separate EEG manual, including but not limited to resting and evoked stimuli.  Placing  of 
electrodes (if possible according to the international 10/20 system) must be documented.  
Recording should last about 10  minutes in the wake  state, a nd if possible, recording 
should end with a nap period. Data will be collected in electronic format in E uropean 
Data Format for centralized reading. An EEG manual will be provided.  
15.6 Optional Biomarker Analysis  
Additional biomarker samples will be acq uired from all subjects for whom the caregiver 
provide s separate informed consent for purification of DNA, and plasma, to allow for 
identification of secondary pathogenic variants and metabolic profile s. 
Two tubes of blood will be collected at baseline for biomarker plasma and biomarker 
DNA and one tube of blood will be collected  at End of Treatment  (Day 84)  for isolation 
biomarker  plasma. DNA will be used to identify secondary pathogenic variants that may 
be present (e.g. micr odeletions encompassing 2q21.3 )18 and plasma for quantification of 
metab olites (e.g. glutamic acid )19. This data will not be captured in the CSR.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 58 of 83 16. SAFETY DEFINITIONS, RECORDING, REPORTING , AND 
 RESPONSIBI LITIES   
The timing and frequency of safety assessments are described in Table  1 and Section  15. 
16.1 Adverse Events  
16.1.1  Definitions  
The definitions for TEAEs, AEs, and SAEs are given below. The Principal Investigator is 
responsible for ensuring th at all study center staff are familiar with the content of this 
section . Any AE experienced by the subject between the screening  visit (Day -28) and up 
to completion of the follow -up period after the last administration of study drug (Day  98 
follow -up phone visit) must  be recorded on t he eCRF, regardless of the severity of the 
event or its relationship to study treatment.  
Adverse Event  (AE)  
An AE is defined as any u ntoward medical occurrence in a clinical investigation subject, 
administered a pharmaceutical product, and which  does not n ecessarily have a causal 
relationship with th is treatment . An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding) , symptom or disease temporally 
associated with the use of a medicinal (investigation al) product , whether or not related to 
the medic inal (investigational) product.  
Determination of whether an abnormal laboratory value meets the definition of an A E 
will be made by the investigator . Although abnormal laboratory values  are typically not 
considered AE s, the following considerations may result in an abnormal laboratory value 
being considered an AE:  
• A laboratory test result meets the criteria for an SAE  
• A laboratory test result requires the subjects to receive specific corrective therapy  
• A laboratory abnor mality that the investigator considers to be clinically 
significant  
Any intolerance that triggers a dose reduction during the titration period must  be 
documented as an AE. 
Treatment -Emergent Adverse Event  (TEAE)  
A treatment -emergent adverse event (TEAE) is  defined as an AE with an onset that 
occurs after receiving study drug (AE start date ≥  first dose date) and within 30  days after 
receiving the last dos e of study drug (AE start date minus  last dose date ≤  30), or an AE 
that occurs pre -treatment but worsen s post treatment . 
Serious Adverse Event  (SAE)  
An SAE  is any untoward medical occurrence that at any dose : 
• Results in death  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 59 of 83 • In the view of the i nvestigator, plac es the subject at immediate risk  of death (a  
life-threatening  event); however, this does not inc lude an event that, had it 
occurred in a more severe form, might have caused death  
• Requires in patient  hospitalization  or prolongs existing hospitalization . Planned 
hospitalizations will NOT be reported as an SAE unless categorized as otherwise 
medically important  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Is otherwise medically important: Important medical  events that may not result in 
death, be life -threatening or require hospitalization  may be considered a serious 
adverse drug experience, when based on appropriate medical judgment , they may 
jeopardize the subject or the subject may require medical or surg ical intervention 
to prevent one of the out comes listed in this definition  
16.1.1.1  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment, including 
hospitalization that is part  of the study design will not be considered an SAE, even if the 
subject is hospitalized . The study center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was 
scheduled prior to obtaining the infor med cons ent to participate in the study  
• The condition requiring the prescheduled or elective procedure or routinely 
scheduled treatment was present before and did not worsen or progress in the 
opinion of the investigator  between the informed consent and  time of procedure or 
treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the 
sole reason for the int ervention or hospital admission  
16.1.1.2  Recording of Adverse Events  
For the purposes of this study, any detrimental change in the subject’s condition, from the 
screening visit  (Day -28) and up to completion of the follow -up period after the last 
administration of study drug (Day  98 follow -up phone visit) should be considered an AE 
and must be recorded on the eCRF.  
All SAEs and AEs will be recorded starting from the screening visit (Day -28). 
All ongoing A Es should be followed up for 30  days after the last administration of study 
drug, with the exception of any ongoing study drug -related AEs, which should be 
followed until resolution, unless in the investigator’s opinion, the AE is unlikely to 
resolve due to the  subject ’s underlying disease. Any new SAEs occurring up to 28  days 
after the last administration of study  drug (Day  98 follow -up phone visit) should be 
reported  according to Section  16.1.1.6 . 
At any time after the follow -up visit , if an investigator learns of an SAE that can be 
reasonably related to study drug, he/she should prom ptly notify Ovid Therapeutics Inc.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 60 of 83 The severity of AEs and SAEs will be graded using the National Cancer Institute 
Common Terminology Criteria for  Adverse Events (CTCAE, Version  4). Any AE not 
listed in the CTCAE will be graded as follows:  
 
Severity Grade  Definition  
1 Mild AE  
2 Moderate AE  
3 Severe or  medically significant AE  
4 Life-threatening AE  
5 Death related to AE  
 
It is important to distinguish b etween serious and severe AEs. Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Section  16.1.1 . 
An AE of severe intensity need not nece ssarily be considered s erious. For example, 
nausea that persists for several hours may be considere d severe nausea, but not a n SAE.  
On the other hand, a stroke that results in only a limited degree of disability may be 
considered a mild stroke but would be a n SAE.  
16.1.1.3  Abnormal Labor atory Values/Vital Signs  
Laboratory/vital sign  abnormalities should be reported as AEs if any one of the following 
criteria is met:  
• Any criterion for an SAE is fulfilled  
• The laboratory/vital signs abnormality causes the subject  to discontinue from the 
study treatment  
• The laboratory/vital signs abnormality causes the subject  to interrupt the study 
treatment  
• The laboratory/vital signs abnormality causes the subject  to modify the dose of 
study treatment  
• The investigator believes th at the abnormality should be reported as an AE  
• If an abnormal laboratory value or vital sign is associated with clinical signs and 
symptoms, the sign or symptom should be reported as an AE and the associated 
laboratory result or vital sign should be consid ered additional information that 
must be c ollected on the relevant eCRF  
16.1.1.4  Deaths  
Should a death occur within the study period or within 60  days after the last 
administration of study drug  an AE form and an SAE form should be completed, 
detailing the AE that resulted in the death ( death is an outcome, not an event).  The SAE 
must be reported to the  Medical Monitor within 24  hours. The report should 
contain a comment regarding the co -involvement of progression of disease, if 
appropriate, and should assign m ain and contributory causes of death.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 61 of 83 16.1.1.5  Relationship to Study T reatment  
The investigator will assess the causality/relationship between the study drug and the AE 
and record that assessment in the eCRF. The investigator should use medical judgment  to 
determine whether there is a “reasonable causal relationship”, including all relevant 
factors such as temporal course and latency, results from de -challenge or re -challenge, 
pattern of the reaction, known pharmacological properties of the produc t, and alternative 
explanations, such as other drugs, medical history, and concomitant diseases . 
The expression “reasonable causal relationship” means to convey in general that there are 
facts (evidence) or arguments to suggest a causal relationship. Assessment will be 
documented on the AE and SAE form.  
The relationship should be assessed according t o the following criteria:  
• No Reasonable Possibility: The relationship of the clinical event to the study drug 
makes a causal relationship unlikely, or other drugs, therapeutic interventions or 
underlying conditions provide a sufficient explanation for the observed event.  
• None (intercurrent event): An event that is not and cannot be related to the 
study drug, such as subject  is a passe nger in a road traffic accident  
• Unlikely (remote): Relationship is not likely, such as a clinical event 
including laboratory test abnormality with temporal relationship to drug 
administration which makes a causal relationship improbable and in which 
other drugs, chemicals or underlying disease provide plausible 
explanations  
• Reasonable Possibility: The relationship of the clinica l event to the study drug 
makes a causal relationship possible, and other drugs, therapeutic interventions, or 
underlying conditions do not provide a sufficient explanation for the observed 
event.  
• Possible: Relationship may exist, but event could have been  produced by 
the subject ’s condit ion or treatment or other cause  
• Probable: Relationship is likely, the AE abates upon discontinuation of 
study drug and cannot be due to the subject ’s condi tion 
• Definite: Strong relationship, the event abates upon discontinu ation of 
study drug and, if applicable, re-appears upon repeat exposure  
For the purposes of AE and SAE assessment, the causality criteria of Possible, Probable , 
and Definite are considered to represent a “r easonable causal relationship”. Conversely, 
the ca usality criteria of None or Unlikely are not considered to meet this threshold.  
For an AE to be a suspected study drug-related event  there should be at least a reasonable 
possibility of a causal relationship between the study drug and the AE.   
16.1.1.6  Reporting o f Serious Adverse E vents  
Investigators and other study center staff must inform appropriate  representatives 
of any SAE that occurs  (whether or not attributable to the study drug)  in the study  within 
24 hours  (i.e. immediately but no later than the end of th e next business day) or  when he 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4  Page 62 of 83 or she becomes aware of it . It is the i nvestigator’s responsibility to ensure that SAE 
reporting procedures are followed appropriately.  
All SAE reports must be faxed to the followi ng number within 24  hours:  
 
 
  
  
 
 
 
 
 
In a study -related medical emergency situation, when assigned Medical Monitors for a 
study cannot be reached by a caller, an on -call Physician can be reached 24 hours per 
day, 7 days per week via the  
 
(chargea ble telephone number allowing a global reac h from both landline s and mobile 
phones)  
 
On this internet page, a list of country-specific toll-free telephone numbers is provided. It 
should be noted that not all countries globally have access to toll-free numbers 
as indicated on the “24/7 Medical Help Desk” index. Countries without toll -free 
numbers need to dial the chargeable number as indicated above. Furthermore, toll-free 
numbers are not available from mobile phones. 
The  will work with the investigator to compile all the necessary 
information and ensure that the appropriate Ovid Therapeutics Inc. 
representative receives a report within one day (24 hours) for all fatal and life-
threatening cases and within 5 days for all other SAEs. 
Follow-up information on SAEs must also be reported by the investigator 
within the same 
time frames. 
If a non-serious AE becomes serious, this and other relevant follow-up information must 
also be provided to  within one day as described above. For a non-serious AE that 
become serious but which is not fatal or life-threatening a report should be 
received within 5 days. 
The following variables will be recorded for each AE: verbatim/AE description, time and 
date for AE start and stop, maximum intensity, seriousness, causality rating, whether 
or not the AE caused the subject to discontinue, and the outcome. 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 63 of 83 All SAEs hav e to be reported, whether or not considered causally related to the 
investigational pro duct or to the study procedures . All SAEs will be recorded in the 
eCRF . The investigator  is responsible for informing the Ethics Committee of the SAE as 
per local requirements . The investigator should report to , who will forward the 
report to the appropriate Ovid Therapeutics Inc.  representative.  
16.1.2  Overdose  
An overdose is any dose of study treatment administered to a subject or taken by a 
subject that exceeds the  dose assigned to the subject according to the protocol. Overdoses 
are not considered AEs and should not be recorded as an AE on the eCRF; however, all 
overdoses must be recorded on the overdose form and faxed to the  Safety Group 
within 24 hours of th e study center becoming aware of the overdose . An overdose must 
be reported to the  Safety Group even if the overdose does not result in an AE. If an 
overdose results in an  AE, the AE must be recorded. If an overdose results in an SAE, 
both the SAE and  overdose forms must be faxed to the  Safety  Group . If no AE is 
observed, this should be clearly stated in the report . 
16.1.3  Pregnancy  
Females  of child -bearing  potential (not surgically sterile) will undergo serum beta-human 
chorionic gonadotrophin (ß -hCG) pregnancy test at the times shown in Table  1. Any 
female subject  with a positive pregnancy test result at Screening  or Baseline  must be 
excluded from the study. A ser um ß -hCG pregnancy test must be performed if any 
woman is suspected of becoming pregnant during the study.  
If pregnancy occur s, study drug must be discontinued immediately. Pregnancy itself is 
not regarded as an AE unless there is a suspicion that the stud y drug may have interfered 
with the effectiveness of a contraceptive medication. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, normal birth or congenital 
abnormality) must be followed up and documented even after t he subject  has been 
withdrawn from the study.  
All reports of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages 
should also be reported and handled as SAEs. Elective abortions without complications 
should not be handled as AEs. All o utcomes of pregnancy must be reported to Ovid 
Therapeutics Inc.  on a pregnancy outcomes report form.  
16.1.4  Medical Emergency  
In a medical emergency requiring immediate attention, study center staff will apply 
appropriate medical intervention, according to standa rds of car e. The i nvestigator should 
contact the study Medical Director .  
16.1.5  Safety Responsibilities  
16.1.5.1  Investigator  
The investigator responsibilities include:  
• Monitor and record all AEs and SAEs, regardless of severity or relationship to 
study treatment  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 64 of 83 • Determine the seriousness, relationship, and severity of each event  
• Determine the onset and resolution dates of each event  
• Complete an SAE form for each SAE and fax it to  Safety within 24  hours 
of the study center becoming aware of th e event  
• Pursue SA E follow -up inform ation actively and persistently  
• Ensure all AE and SAE reports are supported by documentation in the subject’s 
medical records  
• Pursue AE follow -up information, if possible, until the event has resolved or 
become stable  
• Report SAEs to local  ethics comm ittees as required by local law  
16.1.5.2  Ovid Therapeutics Inc.  
Ovid Therapeutics Inc.  responsibilities include:  
• Before study center activation and subject enrollment, ensure the study center 
staff reviewed the definitions of AE and SAE and the instruct ions for monitoring, 
recording, and reporting them  
• Notify all appropriate regulatory autho rities, ethics committees, and i nvestigators 
of SAEs as required by local laws within required timeframes  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 65 of 83 17. STATISTICAL EVALUATION  
17.1 Sample Size and Power  
Sample size cal culations for this study are based on the objective of estimating AE rates 
within each active treatment group. The sample size of 25  subjects per group provides 
sufficient precision for estimation of incidence of common AEs. For example, a 2 -sided 
95% conf idence interval (CI) for a true incidence of 25% will estimate that incidence 
with a 17% precision (half -width of the 95% CI).  
While the expected enrol lment  is 25 subjects per treatment group, if enrol lment  
expectations are not realized, the sample size ma y be as low as 20 subjects per group.  A 
sample size of 20 subjects per group provides sufficient precision for estimation of 
incidence of common AEs.  For example, a 2 -sided 95% CI for the true incidence of 25% 
will estimate that inc idence with 19% precis ion. 
 
 
 
 
   
 
 
 
 
 
 
 
 
17.2 Statistical Methods  
Detailed methodology for summary and statistical analyses  of the data collected in this 
study will be documented in a separate Statistical Analysis Plan (SAP), whic h will be 
maintained by  This document may modify the plans outlined in 
the protocol; however, any major modifications of the endpoint definition and/or its 
analysis will also be reflected in a protocol amendment. Adverse events and e fficac y 
variables may be further described by additional subgroups , such as age group,  and 
details of this analysis will be provided in the SAP. Additional unplanned analyses  may 
be required after all planned analyses  have been completed. Any unplanned analyses  will 
be clearly identified in the SAP.  
17.2.1  General Considerations  
All statistical analyses will be performed using Version 9.4 of Statistical Analysis 
Software (SAS®). 
Data summaries will use descriptive statistics (number of subjects [n], mean, standard 
devia tion [SD], Q1, median, Q3, minimum, and maximum) for continuous variables, and 
frequency and percentage for categorical and ordinal variables . If there are missing 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 66 of 83 values, the number missing will be presented, but without a percentage . All data c ollected 
will be included in by -subject data listings.  
Unless otherwise specified, all tests will be 2 -tailed using a 0.05 level of significance . All 
CIs will be 2 -sided 95%  CIs. 
17.2.2  Statistical Analysis Sets  
The following 4 analysis sets will be included:  
Safety Analysis Set  
The Safety Analysis S et (SS) will consist of all subjects who receive at  least one dose of 
study drug. Subjects will be analyze d according to the treatment they actually receive. 
The SS will be the primary analysis set for safety analyses . 
Intent-to-Treat Set  
The Intent -to-Treat set will consist of all subjects who are randomized , whether or not 
study drug is received.  Subjects will be analyzed according to their randomized group.  
Full Analysis Set  
The Full Analysis Set (FAS) will consist of a ll randomized subjects who receive at least 1 
dose of study drug, and have at least 1 efficacy evaluation after receiving study drug.  
Subjects will be analyzed according to their randomized group.  The FAS will be the 
primary analysis set for efficacy analy ses. 
Per Protocol Set  
The Per Protocol Set is a subset of the FAS that includes all subjects who complete  the 
Week  12 visit, and have no significant protocol violations that are deemed to impact 
efficacy. These violations include but are not limited to violations of inclusion/exclusion 
criteria, less than 80% study drug compliance, and usage of prohibited concomitant 
medications . Further details will be provided in the SAP . Subjects will be analyzed 
according to their randomized group.  
17.2.3  Baseline, Efficacy , and Safety Variables  
All baseline efficacy and safety variables will be presented using descriptiv e statistics by 
treatment group . The 2-sided 95% CIs will be provided where meaningful .  
More details of subgroup analysis will be provided in the SAP.  
17.2.3.1  Baseline Variables  
Baseline variables include:  
• Demographic characteristics: age, age group (adolescents aged 13 to 17 versus  
adults aged 18 to 49 years), gender, race, and ethnicity  
• Enrollment by Study center/ geographic region  
• Presence of baseline comorbidities  
• Baseline psychometric measu res/scales  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 67 of 83 • Prior and concomitant medications  
• Medical and surgical history  
17.2.3.2  Safety Variable s 
The following safety variables will be evaluated:  
• SAEs, and TEAEs throughout the study , TEAEs leading to study discontinuation, 
treatment -related TEAEs, and TEAEs of special interest  
• Clinical safety labo ratory values at Weeks  6 and 12  
• Suicidality  (using t he ABC –C Irritability subscale) at Weeks  6 and 12  
• Vital signs  at Weeks  6 and 12  
• EEG and seizure diary assessment s from baseline to end-of-study  
• Physical Exam at weeks 6 and 12  
17.2.3.3  Efficacy Variables  
 
 
  
  
  
  
  
 
  
 
 
  
   
  
 
 
  
  
  
        
   

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 68 of 83   
  
 
 
          
 
17.2.4  Methods of Statistical Analyses  
The SS and FAS will be used for safety and efficacy data a nalysis , respectively. Subjects 
in the FAS will be analyzed according to their randomized treatment arm.  
17.2.4.1  Safety Analysis  
All AEs will be coded using MedDRA  Dictionary Version 19.1  and will be classified by 
MedDRA system organ class ( SOC ) and preferred term ( PT). 
The number and percentage  of subjects who experience at least one TEAE and the 
number and percentage of subjects who experience at least one TEAE within each 
specific SOC and PT will be presented by treatment group. The 95% CIs will be 
displayed for the frequency of TEAEs.  Treatme nt-related AEs will be considered those at 
least possibly related to investigational product based on the investigator’s assessment . 
The number and percentage of subjects r eporting serious AEs, treatment -related AEs, and 
AEs leading to treatment discontinu ation will also be summarized for each treatment 
group by MedDRA SOC and PT.  
Descriptive statistics for laboratory values and vital signs at each time point will be 
summarized by treatment group. Clinically significant laboratory values may be tabulated 
by treatment group.  
Shift tables for laboratory parameters will be presented to sho w the change of normality 
from B aseline to each post baseline visit. For each continuous laboratory parameter, 
results will be categorized as low, normal, or high based on the  laboratory normal ranges. 
Frequencies and percentages will be presented by treatment arm for the shifts in these 
categories (i.e., low to normal, low to high, high to low, e tc.) from baseline to each 
post-treatment assessment time point .  
Tables and graph ical disp lays (such as scatter plots of baseline  versus worst post -baseline 
values) of key safety parameters may be generated to better understand the study drug 
safety profile.  
Concomitant medications will be coded using the World Health Organization Drug  
Dictionary. A table summarizing concomitant medications and by -subject listing of 
concomitant medications will include all medications taken during the study regardless of 
the timing for the start of the medication.  
17.2.4.2   
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 69 of 83  
 
 
 
 
 
 
 
 
17.2.4.3   
 
 
 
 

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 70 of 83 18. DIRECT ACCESS TO SOU RCE DATA/NOTES  
The investigator/institution shall provide direct acce ss to source data/documents for 
study -related monitoring, audits, IRB review and regulatory inspection.  
 
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 71 of 83 19. QUALITY  CONTROL AND QUALITY  ASSURANCE  
19.1 Conduct of the Study  
Ovid Therapeutics Inc.  or  shall implement and maintain quality control and quality 
assurance procedures with written standard operating procedures ( SOPs ) to ensure that 
the study is conducted and data are generated, doc umented and reported in compliance 
with the protocol, GCP and applicable regulatory requirements.  
This study shall be conducted in accordance with the provisions of the Declaration of 
Helsinki (October 1996) and all revisions thereof, and in accordance wit h Food and Drug 
Administration  (FDA) regulations (C ode of Federal Regulations , Sections 312.50 and 
312.56) and with ICH Guidelines on G CP (CPMP 135/95).  
The investigator may not deviate from the protocol without a formal protocol amendment 
having been esta blished and  approved by an appropriate IRB, except when necessary to 
eliminate immediate hazards to the subject or when the change(s) involve (s) only 
logistical or administrative aspects of the study. Deviations must be reported to  
and the IRB per local guidelines.  
19.2 Study Monitoring  
The inv estigator shall permit the Study Center Monitor to review study data as frequently 
as deemed necessary to ensure that data are being recorded in an adequate manner and 
that protocol adherence is satisfacto ry. 
The investigator shall access medical records for the Study Center Monitor so that entries 
in the eCRFs may be verified. The investigator, as part of his /her responsibilities, is 
expected to co -operate with  in ensuring that the stu dy adheres to GC P 
requirements.  
The investigator may not recruit subjects into the study until such time that a site visit, or 
with the agreement of Ovid Therapeutics Inc. , attendance at the investigator meeting, has 
been made by a n Ovid Therapeutics Inc.  or  monitor to conduct a detailed review of 
the protocol and eCRF.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 72 of 83 20. ETHICS  
20.1 Institutional Review Board  
Prior to the start of the study, the investigator is responsible for ensuring that the protocol 
and ICF have been reviewed  and approved by a relevant IRB. The IRB shal l be 
appropriately constituted and perform its functions in accordance with F DA, ICH/GCP, 
and lo cal requirements as applicable.  
The IRB shall approve all protocol amendments (except for logistical or administrative 
changes), written ICFs  and documents updates, subject recruitment procedures 
(e.g. advertisements), written information to be provided to the subject s, 
Investigator’s  Brochure, available safety information, information about payment and 
compensation available to subjects, the i nvestigators curriculum vitae and/or other 
evidence of qualifications and any other  documents requested by the IRB and Regulatory 
Authority (Competent Authority) as applicable.  
When required, the IRB  and R egulatory Authority must be notified of completion or 
termination of this study, and sent a copy of the study synopsis in accordance with 
necessary timelines.  
20.2 Written Informed Consent  
Prior to performing any study -related activities under this protocol, including screening 
tests and assessments, written i nformed consent from the parent/caregiver (or legally 
authorized representative) and assent , as appropriate , from the potential subject must be 
provided separately for each subject and their legally authorized caregiver  in accordance 
with local practice and  regulations .  
 Should a subject gain the ability to sufficiently 
comprehend the situation and consent during the course of the study, written informed 
consent or verb al assent will be documented as required or recommended by the 
institution’s IRB.  
The background of the proposed study, the procedures, th e benefits and risks of the stud y, 
and that the study participation is voluntary for the subject must be explained to  the 
subject (or the subject’s legally authorized representative). The subject’s caregiver must 
be given sufficient time to consider whether to participate in the study.  
The form of consent to be obtained will depend on the condition of the subject as 
determined by the Principal Investigator. The ICF, as specified by the clinical site’s IRB, 
must follow the Protection of Human Subjects regulations listed in the Code of Federal 
Regulations, Title 21, Part 50.  
A copy of the sig ned and dated ICF (and assent as  applicable) must be  given to the 
subject ’s caregiver or legally authorized representative . The signed and dated ICF will be 
retained with the study records . Local regulations must be followed with  respect to the 
final disposition of the original (wet sign ature) and copie s of the signed and dated ICFs.  
The ICF for subject participation must also be available as part of the subject ’s medical 
record  for review by the site’s dedicated study monitor or any authorized auditor of Ovid 
Therapeutics Inc.  or regula tory authorities.  

Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 73 of 83 All ICFs must be approved by the appropriate IRB and by Ovid Therapeutics Inc . The 
ICF must not be altered without the prior agreement of the relevant IRB and Ovid 
Therapeutics Inc.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 74 of 83 21. DATA PROTECTION  
Prior to any testing under this protocol , including screening test and assessments, subjects 
must also provide all authorizations required by local law ( e.g. Protected Heath 
Authorization in North  America).  
The subject will not be identified by name in the eCRF or in any study reports, and these  
reports will be used for research purposes only . Ovid  Therapeutics  Inc., its partners and 
designees, IRBs, and various government health agencies may inspect the records of this 
study. Every effort will be made to keep the subject’s personal medical infor mation 
confidential.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 75 of 83 22. CONFLICT OF INTEREST  
The i nvestigators should address potential conflicts of interest (e.g. financial interest in 
Ovid or partnering companies) with the caregivers before the caregive r makes a decision 
to participate in the study.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 76 of 83 23. CLINICAL TRIAL STEER ING COMMITTEE  
A Clinical Trial Steering Committee will oversee all aspects of study design and 
execution  and provide oversight and overall direction for the study . The committee 
members will contribute to the study design, protocol, pro tocol amendments, and ensure 
ethical conduct of study . The c ommittee members will champion the study for 
investigators and study centers and ensure the well -being, rights, and safety of study 
participants, and will be responsible for communication of study  results.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 77 of 83 24. CHANGES TO FINAL STU DY PROTOCOL  
All protocol amendments must be submitted to the IRB and regulatory authori ties as 
required by local law. Protocol modifications that affect subject safety, the scope of the 
study, or the scientific quality of stud y must be approved by the IRB before 
implementation of such modifications to the conduct of the study . If require d by local 
law, such modifications must also be approved by the appropriate regulatory agency prior 
to implementation.  However, Ovid Therapeuti cs Inc.  may at any time amend the protocol 
to eliminate an apparen t immediate hazard to a subject . In this case, appropriate 
regulatory authorities will be notified subsequent to the modification . In the event of a 
protocol modification, the ICF may requir e similar modifications.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 78 of 83 25. DATA HANDLING  AND RECORD KEEPING  
25.1 Electronic Case Report Forms/ Source Data Handling  
The investigator shall be provided with standardized  eCRFs and shall ensure that all data 
from subject visits are promptly entered into the eCRFs in accordance with the specific 
instructions given. The investigator must sign each eCRF to verify the integrity of the 
data recorded.  
A list of the normal ranges for all laboratory tests to be undertaken forms part of the 
documentation to be collated  prior to study start. If a central laboratory has been selected 
to conduct any or all tests, it is essential that all samples be analyze d at that laboratory.  
The investigator must maintain source documents, such as laboratory reports, EEGs, 
consultation r eports, and complete medical history an d physical examination reports.  
Data to be recorded directly on the eCRFs (i.e. no prior written or electronic record of 
data) and considered to be source data must be identified in the protocol.  
25.2 Retention of Essentia l Documents  
The minimum retention time for study records will meet the strictest standard applicable 
to that study center , as dictated by institutional requirements or local laws or regulations . 
Prior to proceeding wi th destruction of records, the i nvestig ator must notify Ovid 
Therapeutics Inc.  in writing and receive written authorization from them to destr oy study 
records. The i nvestigator must also notify Ovid Therapeutics Inc.  of any changes in 
archival arrangements, including but not limited to, archiva l at an offsite facility or 
transfer of owners hip if the i nvestigator leaves the study center.  
The investigator/institution should take measures to prevent accidental or premature 
destr uction of these documents.  
Essential documents sho uld be retained until  at least 5  years after the last approval of a 
marketing application in an  ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least 5  years have elapsed since the 
formal discontinuation of clinical  development of the investigational product. These 
documents should be retained for a longer period, however, if required by the applicable 
regulatory requirements or by an agreement with Ovid Therapeutics Inc . It is the 
responsibility of Ovid Therapeutics  Inc. to inform the investigator/institution as to when 
these documents no longer need to be retained.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 79 of 83 26. FINANCING AND INSURA NCE  
Ovid Therapeutics Inc.  shall carry an insurance policy to cover compensation of subjects’ 
health injuries arising from the study. Subject s who incur a study -related injury may be 
treated (and other necessary measures taken) at the study center and/or another medical 
institution.  If it is necessary to compensate for the treatment, Ovid Therapeutics Inc.  will 
cover the cost  and shall not impose on the subject the burden of proving the causal 
relation between the study and the injury.  
If any of the following is confirmed, Ovid Thera peutics Inc.  may refuse or restrict the 
payment of the compensation:  
• A serious GCP or protocol deviation by the investigator or sub -investigator 
(except deviation medically necessary to avoid an immediate hazard to study 
subjects)  
• Intentional act or neglig ence on the part of the investigator or sub -investigator or 
malpractice thereby  
• Injury caused by unlawful act or delinquency of a third part y 
• Injury caused by intentional a ct or negligence of the subject  
If compensation becomes necessary for a study -relate d injury, the study center  will 
promptly notify Ovid Therapeutics Inc.  and will co -operate with Ovid Therapeutics Inc.  
and its insurer (or their legal representatives) in their handling thereof.  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 80 of 83 27. REGISTRATION OF STUD Y AND DISCLOSURE OF RESULTS  
Ovid Therapeu tics Inc.  will register the study and post study results regardless of 
outcome on a publicly accessible website in accordance with the applicable laws and 
regulations. Ovid Therapeutics Inc.  shall retain the ownership of all data. When the study  
is complet e Ovid Therapeutics Inc.  shall arrange the analysis and tabulation of data. A 
clinical study report shall then be prepared, which may be used for publication, 
presentation at scientific meetings or submission to regulatory authorities. All proposed 
publica tions based on this study must be subject to Ovid Therapeutics Inc. ’ approval 
requirements.  
  
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 81 of 83 28. SIGNATURE OF INVESTI GATOR  
I agree to conduct the study outlined above in accordance with the terms and conditions 
of the protocol, ICH guidelines for GCP and with applicable regulatory requirements. All 
information pertaining to the study shall be treated in a confidential manner.  
 
 
 
   
Investigator Signature  
 
 
  Date (day/month/year)  
   
Print Name  
 
 
   
 
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 82 of 83 REFERENCE LIST                  
 
1 Williams CA, Beaudet AL, Clayton -Smith J, Knoll JH, Kyllerman M, Laan LA, et 
al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med 
Genet. 2006;140(5):413 -8. 
2 National Institute of Neurological Disorders and Stroke. 
http://www.ninds.nih.gov/disorders/angelman/angelman.htm  
3 Egawa K, Kitagawa K, Inoue, K. Takayama M, Takayama C, Saitoh S, et al. 
Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a 
mouse model of Angelman syndrome. Sci Tr ansl Med. 2012;4 (163) :163.  
4 Dissel S, Angadi V, Kirszenblat L, Suzuki Y, Donlea J, Klose M, et al. Sleep 
restores behavioral plasticity to Drosophila mutants. Curr Biol. 
2015;25(10):1270 -81. 
5 Berry JA, Cervantes -Sandoval I, Chakraborty M, and Davis RL. S leep Facilitates 
Memory by Blocking Dopamine Neuron -Mediated Forgetting. Cell. 
2015;161(7):1656 -67. 
6 Brickley SG and Mody I. Extrasynaptic GABA(A) receptors: their function in the 
CNS and implications for disease. Neuron. 2012;73(1):23 -34. 
7 Ramamoorthi K , and Lin Y. The contribution of GABAergic dysfunction to 
neurodevelopmental disorders. Trends Mol Med. 2011;17(8):452 -62. 
8 Egawa K, and Fukuda A. Pathophysiological power of improper tonic GABA(A) 
conductances in mature and immature models. Front Neural Circuits. 2013;7:170 . 
9 Deidda G, Bozarth IF, and Cancedda L. Modulation of GABAergic transmission in 
development and neurodevelopmental disorders: investigating physiology and 
pathology to gain therapeutic perspectives. Front Cell Neurosci. 2014;8:119.  
10 Gaboxadol (OV101) Investigator’s Brochure. Edition 01. 14 June 2016.  
11 Study 10218. Chronopharmacokinetics and Food Interaction (Merck 026) – open 
label, single dose, 4 -way cross -over. Dose level 15  mg with two morning doses and 
2 evening doses with and wi thout food. Complete Clinical Study Report.  
12 H. Lundbeck A/S. Determination of gaboxadol (Lu 02 -030) and metabolites 
(glucuronide and sulphate of gaboxadol) in urine from human volunteers. 
Study  99096. Report No: 263/823. 2003.  
13 Phillips et al (Bone Abst racts [2015] 4 P136).  
14 Grieco JC, Ciarlone SL, Gieron -Korthals M, Schoenberg MR, Smith AG, Philpot 
RM, et al. An open -label pilot trial of minocycline in children as a treatment for 
Angelman - syndrome. BMC Neurol. 2014;14:232.  
 
Ovid Therapeutics Inc.  CONFIDENTIAL  24 October 2017  
OV101 -15-001 (OV101 ) 
Protocol Version 4    Page 83 of 83  
15 Wondra VC, Pitetti KH, and Beets MW. Gait parameters in children with motor 
disabilities using an electronic walkway system: assessment of reliability. Pediatr 
Phys Ther. 2007;19(4):326 -31. 
16 Prosser LA, Lauer RT, VanSant AF, Barbe MF, and Lee SC. Variability and 
symmetry of gait in early walkers with and without bilateral cerebral palsy. Gait 
Posture. 2010;31(4):522 -6. 
17 Aman MG, Singh NN, Stewart AW, and Field CJ. The aberrant behavior checklist: 
a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 
1985;89(5):485 -91. 
18 Neubert G, von Au K, Drossel K, Tzschach A, Horn D, Nickel R, et al. Angelman 
syndrome and severe infections in a patient with de novo 15q11.2 -q13.1 deletion 
and maternally inherited 2q21.3 microdeletion. Gene. 2013 Jan 10;512(2):453 -5. 
PMID  23124039.  
19 West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, et al. 
Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in 
the blood plasma of children. PLoS One. 2014;9(11):e112445. PMID  25380056 . 